Antiprotozoal Nor-Triterpene Alkaloids from Buxus sempervirens L.

Szabó, Lara U.; Kaiser, Marcel; Mäser, Pascal; Schmidt, Thomas J.

doi:10.3390/antibiotics10060696

Open AccessArticle

Antiprotozoal Nor-Triterpene Alkaloids from Buxus sempervirens L.

¹

Institute of Pharmaceutical Biology and Phytochemistry (IPBP), University of Münster, PharmaCampus Corrensstraße 48, D-48149 Münster, Germany

²

Swiss Tropical and Public Health Institute (Swiss TPH), Socinstrasse 57, CH-4051 Basel, Switzerland

³

University of Basel, Petersplatz 1, CH-4003 Basel, Switzerland

^*

Author to whom correspondence should be addressed.

Antibiotics 2021, 10(6), 696; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10060696

Submission received: 19 May 2021 / Revised: 7 June 2021 / Accepted: 8 June 2021 / Published: 10 June 2021

(This article belongs to the Special Issue Antiprotozoal Activity of Natural Products)

Download

Browse Figures

Versions Notes

Abstract

:

Malaria and human African trypanosomiasis (HAT; sleeping sickness) are life-threatening tropical diseases caused by protozoan parasites. Due to limited therapeutic options, there is a compelling need for new antiprotozoal agents. In a previous study, O-tigloylcyclovirobuxeine-B was recovered from a B. sempervirens L. (common box; Buxaceae) leaf extract by bioactivity-guided isolation. This nor-cycloartane alkaloid was identified as possessing strong and selective in vitro activity against the causative agent of malaria tropica, Plasmodium falciparum (Pf). The purpose of this study is the isolation of additional alkaloids from B. sempervirens L. to search for further related compounds with strong antiprotozoal activity. In conclusion, 25 alkaloids were obtained from B. sempervirens L., including eight new natural products and one compound first described for this plant. The structure elucidation was accomplished by UHPLC/+ESI-QqTOF-MS/MS and NMR spectroscopy. The isolated alkaloids were tested against Pf and Trypanosoma brucei rhodesiense (Tbr), the causative agent of East African sleeping sickness. To assess their selectivity, cytotoxicity against mammalian cells (L6 cell line) was tested as well. Several of the compounds displayed promising in vitro activity against the pathogens in a sub-micromolar range with concurrent high selectivity indices (SI). Consequently, various alkaloids from B. sempervirens L. have the potential to serve as a novel antiprotozoal lead structure.

Keywords:

Buxus sempervirens L.; nor-cycloartane alkaloids; antiprotozoal activity; natural product isolation; structure elucidation

1. Introduction

Buxus sempervirens L. (common box; Buxaceae) is an evergreen shrub or small tree, with nor-triterpene alkaloids of the nor-cycloartane type as its main chemical constituents. Decoctions of leaves were ethnopharmacologically used against a variety of indications, including malaria [1,2].

Malaria is a life-threatening infectious disease caused by protozoans of the genus Plasmodium. The vector of these parasites is the infected female Anopheles mosquito. The World Health Organization (WHO) estimated that 229 million malaria cases and 409,000 malaria deaths occurred worldwide in 2019. The incidence has remained virtually unchanged in recent years and, because of the coronavirus pandemic, the WHO estimated 100,000 additional deaths in 2020. The progress in the fight against malaria has stalled. There is a high incidence of treatment failure due to resistance and, thus, the development of new antimalarial drugs is indispensable.

Phytochemical studies on B. sempervirens L. led to the isolation of almost 200 alkaloids [3], which have displayed interesting bioactivities including antibacterial, antimycobacterial, antimalarial, and acetyl- and butyryl-cholinesterase inhibition activity [4,5].

In a previous study by our group [6], O-tigloylcyclovirobuxeine-B, after bioactivity-guided isolation from the dichloromethane extract of B. sempervirens leaves, was identified as the constituent mainly responsible for the plant’s antiplasmodial activity. It appeared likely that further congeneric alkaloids also yield contributions to the overall antiplasmodial effect of the total leaf extract. Moreover, a lupane triterpene of B. sempervirens L. showed prominent bioactivity even against drug-resistant malaria parasites [7]. Consequently, the isolation, as well as the antiplasmodial testing of further Buxus-alkaloids, is of great interest.

In a recent study [8], it was determined that the alkaloid-enriched fraction of Pachysandra terminalis (Buxaceae) possessed promising activity against another protozoan parasite, Trypanosoma brucei rhodesiense (Tbr), the causative agent of East African sleeping sickness, a poverty-related neglected tropical disease. This plant contains aminosteroids structurally related to the nor-triterpene alkaloids of B. sempervirens L. Furthermore, an isolated compound of B. sempervirens L., cyclovirobuxeine-B, was found to be highly active and selective against Tbr in vitro [9]. These findings suggested that additional Buxus-alkaloids could likewise represent strong trypanocides. The chemotherapeutic agents currently in use against African sleeping sickness (human African trypanosomiasis (HAT)) are toxic and have many other associated disadvantages, such as long hospitalization. Accordingly, there is a compelling need for new treatments.

The aim of this study was the identification and characterization of potent and selective antiprotozoal compounds as lead structures against tropical diseases. For this purpose, we report on the systematic isolation of 25 alkaloids from a B. sempervirens L. leaf extract, including eight new natural products and one compound first described for this plant. The compounds were obtained by centrifugal partition chromatography (CPC), preparative high performance liquid chromatography (prep-HPLC), and column chromatography (CC). Additionally, we present the results of the in vitro testing of the isolated alkaloids against the pathogens of malaria and HAT.

2. Results and Discussion

2.1. Identification of Isolated Buxus-Alkaloids

The isolation scheme of alkaloids from B. sempervirens L. (Scheme 1) consisted of various separation methods such as CPC, prep-HPLC, and CC. It resulted in the isolation of 25 compounds. The structure elucidation and identification of the isolated Buxus-alkaloids were accomplished by UHPLC/+ESI-QqTOF-MS/MS (henceforth termed “LC/MS”) and NMR spectroscopy. Eighteen alkaloids (1–18), with a 9β-19-cyclo-5α-pregnane core skeleton, were isolated in addition to one steroidal alkaloid (19) and six substances, which possess a (9(10→19))abeo-5α-pregnane core skeleton (20–25) (Figure 1). The spectral data of the previously known compounds (Table 1), O-tigloylcyclovirobuxeine-B (1) [6,10,11], cyclovirobuxeine-B (2) [9,12], cyclomicrophylline-A (5) [13,14], cyclomicrophyllidine-A (6) [15,16], N-benzoyl-O-acetyl-cycloxo-buxoline-F (9) [10], N-benzoyl-cycloxo-buxoline-F (10) [10], N_b-dimethylcycloxobuxoviricine (12) [17], (E)-cyclobuxophyllinine-M (13) and (Z)-cyclobuxophyllinine-M (14) [18,19], (E)-cyclosuffrobuxinine-M (15) and (Z)-cyclosuffrobuxinine-M (16) [20,21,22], cyclomicrobuxinine (17) [21,23], cyclomicrobuxine (18) [23], irehine (19) [24], 16-α-hydroxybuxaminone (20) [25], N₂₀-acetylbuxamine-E (21) [26], and N-benzoyl-O-acetylbuxodienine-E (22) [27], were in full agreement with findings reported in the literature. Additionally, 2D-NMR spectra (COSY, HSQC, and HMBC) were evaluated to confirm the identification of the known compounds. To the best of our knowledge, cyclomicrophyllidine-A (6), previously known only from B. microphylla Sieb. et Zucc., has been isolated from the leaves of B. sempervirens L. for the first time.

The eight compounds 3, 4, 7, 8, 11, and 23–25 are described for the first time, to the best of our knowledge.

The molecular formula of compound 3, obtained as a colorless gum, was determined as C₃₂H₅₂N₂O₃ by LC/MS (Figures S5–S7, Supplementary Materials). The ¹H- and ¹³C-NMR spectroscopic data (Table 2; Figures S8–S17, Supplementary Materials) displayed partly similar signals to 1 and differed from 9β-19-cyclo-5α-pregnane by the presence of signals for a methylene instead of a methyl group. The chemical shift of the methylene (δ_C = 67.80; δ_H = 4.05 and 3.79 (1H, d, 11.6 Hz)) suggested a hydroxyl-containing structure. HMBC correlations of the methylene carbon with H-3, H-5, H-8 and H-30 confirmed compound 3 as the C-29 hydroxylated analogue of 1 (Figure 2).

Compound 4, obtained from CPC fraction 2 as a white powder, possesses the molecular formula C₃₃H₅₄N₂O₃ according to LC/MS analysis (Figures S18–S20, Supplementary Materials), which indicates a further methylated analogue of 3. The ¹H- and ¹³C-NMR spectroscopic data (Table 2; Figures S21–S30, Supplementary Materials) displayed great similarity between 4 and 3. In contrast to a monomethylated amine in 3, 4 displayed signals of two magnetically equivalent N-methyl groups at δ_C = 40.71 and δ_H = 2.14 (6H, s), which showed correlation with C-20 in the HMBC experiment. In contrast to compound 3, the structure of 4 possesses a tertiary amine (dimethylamino group) at position C-20 instead of a secondary amine (monomethylamino group) (Figure 2).

For compound 7, the molecular formula was determined as C₃₄H₅₀N₂O₃ by LC/MS (Figures S39–S41, Supplementary Materials). Most signals in the NMR spectra (Table 2; Figures S42–S50, Supplementary Materials) were in common with compound 3. The only difference was observed in the signals of the ester side chain at C-16 of 7, which differed from 3 by the presence of a benzoate moiety instead of a tiglate moiety (Figure 2).

Compound 8, isolated from CPC fractions 5 and 6, displayed the molecular formula C₃₃H₅₀N₂O₂ in LC/MS analysis (Figures S51–S53, Supplementary Materials). The signals of the NMR spectra (Table 2; Figures S54–S62, Supplementary Materials) for the major part were in agreement with the previous 9β-19-cyclo-5α-pregnane derivatives (1–7). In the ¹H-NMR spectrum the two doublet signals (J = 4.6 Hz) of the methylene group at C-19 of the cyclopropane ring could be detected at δ_H = 0.80 and 0.71. This downfield shift in comparison to the corresponding signal in compounds 1–7, which all display the signal for one of the protons at C-19 between δ_H = 0.4 and −0.2, indicates the absence of anisotropic shielding by the Δ⁶ double bond. This observation was in full agreement with the absence of an olefinic proton signal for position 6 and so, in conclusion, the B-ring in 8 is fully saturated [17,28]. In addition, the typical proton signals of a benzoic acid ester at δ_H = 8.06 (m (2H), Pos. 2′/6′), 7.66 (m (1H), Pos. 4′), and 7.53 (m (2H), Pos 3′/5′) could be identified. The carbonyl carbon of the ester resonated at δ_C = 166.74 and showed ³J couplings in the ¹H/¹³C-HMBC spectrum with the protons in position 2 of the A-ring and positions 2′/6′ of the benzoic acid. The proton in position 2, accordingly, displayed the usual chemical shift caused by geminal relationship with an ester group, i.e., δ_H = 5.30 (td (1H), J = 10.9 and 4.8 Hz) [29]. The signals at δ_H = 2.96 (s (3H)) and 2.67 (s (3H)) indicated a Buxus-alkaloid with two monomethylated amino groups at C-3 and C-20. The resulting structure is presented in Figure 2.

For compound 11, the molecular formula was determined as C₂₆H₄₃NO₃ by LC/MS (Figures S71–S73, Supplementary Materials). In the ¹H, ¹³C, and HSQC-NMR spectra for 11 (Table 2; Figures S74–S81, Supplementary Materials) the presence of six sp³ quaternary carbons, five methines, nine methylenes, and six methyl groups were detected. The present compound showed similarity in the NMR spectra with the signals of cyclomicrophylline A (5). For instance, the ¹H/¹³C-HSQC spectrum displayed the typical interactions of the proton in the hydroxylated position 16 at δ_H = 4.31 with δc = 77.20 and the signals of the hydroxylated methylene group in position 29 at δ_H = 3.86 and 3.32 (d, 11.2 Hz) with δc = 64.35. Alternatively, the resonances of the olefinic methine protons are missing, which suggested a saturated B-ring. In the ¹³C-NMR spectrum, a signal at δc = 217.33 could be detected in the low field in the typical shift range of a ketone [29]. The ²J and ³J couplings in the ¹H/¹³C-HMBC spectrum of the ketone carbon with positions 1, 2, 29 and 30 clearly assigned it to C-3. This position also appears plausible from a biosynthetic point of view [28] for the elucidated new structure (Figure 2).

In the +ESI-QqTOF MS/MS spectrum (Figure S121, Supplementary Materials), compound 23 exhibited identical fragmentation (the fragmentation pathway is reported for the first time in Figure S122, Supplementary Materials) with N-benzoyl-O-acetylbuxodienine-E (22). The molecular formula C₃₅H₅₀N₂O₃, derived from the quasimolecular ions (m/z 274.1989 [M + 2H]²⁺, 547.3917 [M + H]⁺) and the resulting 12 double bond equivalents of the two substances, agree. Thus, the present compound’s structure must be very similar to that of the already known congener and represents an isomer of 22. The UV spectrum (Figure S123, Supplementary Materials) of structure 23 indicated the presence of a secondary benzamide with an absorption maximum at 225 nm [10]. The absorption of a diene system, as in compound 22 (λ_max at 237, 245 and 253 nm, Figure S114, Supplementary Materials), was not detectable. The signals of the NMR spectra (Table 3; Figures S124–S133, Supplementary Materials) of 22 and 23 were very similar for the most part. Deviations occurred in the chemical shifts at positions C-11 and C-19 in the A-ring. In the ¹H/¹³C-HSQC spectrum of compound 23, two signals could be detected at δ_H = 5.42 (br s)/δc = 121.95, as well as δ_H = 5.31 (br m)/δc = 119.37, which indicated olefinic structural elements. In the ¹H/¹³C-HMBC spectrum, these signals did not show any interaction with each other, as would be expected in a conjugated Δ^9(11),10(19) system as found in 22. Instead, the chemical shifts agree with a (9-(10→19))abeo-pregnane with the presence of two isolated double bonds, i.e., Δ¹⁽¹⁰⁾ and Δ⁹⁽¹¹⁾ [28,30]. Consequently, compound 23 could be identified as a constitutional isomer of 22 with a double bond between C-1 and C-10, instead of C-10 and C-19 (Figure 2).

For compound 24, the molecular formula was determined as C₂₇H₄₄N₂O by LC/MS. The +ESI-QqTOF mass spectrum (Figure S135, Supplementary Materials) showed protonated ion signals at m/z 207.4721 [M + 2H]²⁺ and m/z 413.0273 [M + H]⁺, in which the intensity of the [M + H]⁺ clearly outweighed the signal of the [M + 2H]²⁺ (as in the +ESI-QqTOF mass spectrum of compound 9, 10 and 21–23). This implied a structure with two nitrogen groups, which have clearly different basicities. The fragmentation in the +ESI-QqTOF MS/MS spectrum (Figure S136, Supplementary Materials) with a neutral loss of 31 Da suggested the presence of a monomethylamino group at C-3 or C-20 (m/z = 382 [M-CH₃NH₂]⁺). The fragment at m/z = 323 [382-CH₃CONH₂]⁺ indicated the neutral loss of an acetamide group (-59 Da). By means of the NMR spectroscopic data (Table 3; Figures S137–S145, Supplementary Materials), compound 24, in analogy with 23, could clearly be assigned to the Buxus-alkaloids with a (9-(10→19))abeo-pregnane backbone and isolated double bonds between C-1 and 10 and between C-9 and 11. The acetamide group, already suspected by the fragmentation, could be located at the nitrogen atom at C-20 by the cross signal of the carbonyl carbon (δ_C = 170.18) with the proton at position 20 (δ_H = 3.99) in the ¹H/¹³C-HMBC spectrum. This amide group has a significantly reduced basicity in contrast to the secondary amine group in position 3, which provides an explanation for the low intensity of the [M + 2H]²⁺ quasimolecular ion in the +ESI-QqTOF mass spectrum. The resulting structure is presented in Figure 2.

The LC/MS analysis (Figures S146–S148, Supplementary Materials) of compound 25 indicated the molecular formula C₂₅H₄₁NO₂. The fragmentation (Figure S148, Supplementary Materials) already gave rise to some structural features that are contained in compound 25. The fragment at m/z 339 [M-(CH₃NH₂)-(H₂O)]⁺ resulted from the loss of a monomethylated amino group, together with the elimination of a hydroxyl group as a water molecule. The following fragment at m/z 321 [339-H₂O]⁺ showed an additional hydroxyl group. By evaluating the NMR spectra (Table 3; Figures S149–S158, Supplementary Materials), compound 25 was clearly identified as a Buxus-alkaloid with a (9-(10→9))abeo-pregnane skeleton and isolated double bonds between C-1 and C-10 and between C-9 and C-11. A methine proton signal at δ_H = 3.84 (δ_C = 73.7 according to the ¹H/¹³C-HSQC spectrum) resonated as a quartet (J = 6.1 Hz) and should therefore be in geminal position with a methyl group and must represent position 20. In the ¹H/¹³C-HMBC spectrum, this proton showed cross peaks with carbons at δ_C = 18.21 (CH₃), 38.63 (CH₂), and 85.50 (quaternary C). The signal at δ_C = 18.21 was assigned the methyl group in position 21 (δ_H = 1.18 (d, J = 6.1)), whereas δ_C = 38.63 could be assigned to the methylene group in position 16. The quaternary carbon at δ_C = 85.50 resonated in the typical shift range of a tertiary alcohol group and could be assigned to position 17. The present alkaloid thus possesses a vicinal diol structure at positions 17 and 20 (Figure 2).

The generic names of the new natural products were chosen based on the existing classification for Buxus-alkaloids [31,32]: O-tigloylcyclomicrophylline-B (3), O-tigloylcyclomicrophylline-A (4), cyclomicrophyllidine-B (7), O-benzoyl-cycloprotobuxoline-D (8), 29-hydroxy-cyclomikuranine-L (11), N-benzoyl-O-acetylbuxadine-E (23), N₂₀-acetylbuxadine-G (24), and 17,20-dihydroxybuxadine-M (25). Compound 24 was concurrently isolated by Xiang et al. [33]. We prefer the systematic generic name N₂₀-acetylbuxadine-G for this substance. The chemical structures of the new natural products are reported in Figure 2.

2.2. In Vitro Antiprotozoal Activity of Isolated Compounds

After isolation, all alkaloids were tested in vitro for antiplasmodial and antitrypanosomal activity against Plasmodium falciparum (Pf) and Trypanosoma brucei rhodesiense (Tbr). Furthermore, to assess their selectivity against the parasites, cytotoxicity against L6 rat skeletal myoblasts, as mammalian control cells, was tested (Table 4).

Compounds 3, 4 and 6–8 showed conspicuous activity against Pf with IC₅₀ values <1.0 µM. The new natural products, O-benzoyl-cycloprotobuxoline-D (8) and cyclomicrophyllidine-B (7), were the most active antiplasmodial compounds with IC₅₀ values of 0.18 and 0.2 µM and SI values of 74 and 145, respectively. Except for compounds 17 (IC₅₀ 10.9 µM) and 18 (IC₅₀ 6.8 µM), all other 9β-19-cyclo-5α-pregnanes (1, 2, 5, 9, 11–16) and the steroidal alkaloid (19) displayed moderate activities with IC₅₀ values in the range of 1.05 to 4.3 µM. The (9-(10→19))abeo-5α-pregnanes (20–25) were less active with IC₅₀ values of >4.0 µM.

Promising antitrypanosomal activities with IC₅₀ values between 1.1 and 1.5 µM were recorded for compounds 2, 6, 8 and 24. In common with the tests against Pf, O-benzoyl-cycloprotobuxoline-D (8) (IC₅₀ 1.1 µM; SI 12) was the most effective antitrypanosomal Buxus-alkaloid in this set of compounds. Cyclomicrophylline-A (5) showed the highest selectivity against Tbr (SI 42). Compounds 1, 4, 5, 7, 9 and 13–16 were moderately active, with IC₅₀ values varying between 2.1 and 3.6 µM. The IC₅₀ values of the other alkaloids against Tbr were >5.7 µM, indicating a low level of activity.

3. Materials and Methods

3.1. Plant Material

The same plant material was used as described previously [11].

3.2. Extraction and Isolation of Alkaloids from the B. sempervirens Leaf Extract

The extraction of plant material, the first part of the isolation procedure, and the isolation of O-tigloylcyclovirobuxeine-B (1) was equal to our previous study (Scheme 1) [11].

After the second CPC separation of Fraction 2 (F2) [11], test tubes 44–47 (7 mg) contained compound 4 as a main constituent. A Sephadex-LH 20 column (15 × 40 cm, flow 0.4 mL/min) was applied for purification of 4 using MeOH (isocratic, 100 mL) as eluent. Compound 4 (2.2 mg) was obtained as a white powder. The CPC test tubes 55–60 consisted of pure compound 6 (11.8 mg). CPC fractions 5 + 6 (103.2 mg), 8 (138.0 mg), and 16 (108.4 mg) were separated on an RP18 phase (Macherey-Nagel, Nucleodur C-18 HTec, 250 × 21 mm, 5 μm) using a H₂O (+0.1% TFA; A): ACN (+0.1% TFA; B) gradient (0 min: 5% B; 5 min: 20% B; 12.5 min: 30% B; 14 min: 32% B; 22 min: 35% B; 35 min: 100% B; and 40 min: 100% B) by prep-HPLC. Fractions 5 and 6 resulted in the isolation of compound 8 (1.6 mg, t_R 20.0 min), 12 (2.8 mg, t_R 27.6 min), 13 + 14 (5.4 mg, t_R 29.2 min), 19 (6.5 mg, t_R 20.8 min), 20 (5.6 mg, t_R 19.2 min), 21 (3.7 mg, t_R 27.2 min), and 22 (4.3 mg, t_R 29.6 min). The separation of fraction 8 yielded substance 3 (6.7 mg, t_R 16.4 min), 7 (4.0 mg, t_R 17.2 min), 15 + 16 (19.6 mg, t_R 28.0 min), and 25 (14.5 mg, t_R 24.4 min). Compound 9 (1.9 mg, t_R 26.2 min), 10 (2.0 mg, t_R 27.0 min), 11 (3.8 mg, t_R 19.0 min), and 24 (7.3 mg, t_R 28.2 min) were obtained by prep-HPLC of fraction 16.

CPC fractions F14 and F18+F19 presented 18 (28.6 mg) and 17 (391.5 mg) as pure compounds, respectively. Compound 23 (10.0 mg) was obtained from the crude dichloromethane extract by CC on silica gel (Merck, type-60, 70–230 mesh). The separation was introduced by gradient elution of ethyl acetate (EtOAc) (100%) until eluates became clear (eluates contained no alkaloid), followed by EtOAc saturated with aq. ammonia (3.5 L, flow 1 mL/min). Six fractions (five alkaloidal) were collected in 20 mL tubes (Bs1, Bs2a, Bs3a, Bs4a, Bs5a (starting from tube 78) and Bs6a). Bs2a was further purified using isocratic aq. ammonia-saturated EtOAc in a smaller silica gel column (flow 0.4 mL/min) and yielded 10.0 mg of compound 23 (white powder).

3.3. Alkaline Hydrolysis of the Esters 1 and 6

The corresponding free alcohols 2 and 5 were obtained from the already isolated compounds 1 and 6 by non-aqueous alkaline ester hydrolysis [34,35]. The esters 1 (32.0 mg) and 6 (4.7 mg) were hydrolyzed with 0.5 N NaOH in a dichloromethane-methanol mixture (9: 1 v/v) at room temperature. The completion of the reaction (1 to 2: 4 ½ h and 6 to 5: 6 d, 14 ½ h) was monitored by thin layer chromatography (TLC plate silica gel 60 F₂₅₄, Merck KGaA, Darmstadt, Germany; mobile phase: butan-1-ol:H₂O:CH₃COOH (10:3:1) (v/v/v), detected with Liebermann-Burchard reagent (acetic anhydride (5 mL), sulfuric acid (5 mL), and ethanol (50 mL), European Pharmacopoeia Reagent)), and the resulting alcohols were purified by extraction (four times with 100 mL dichloromethane). The yield in each case was >85%: 2 (22.8 mg) and 5 (3.2 mg). Since these two compounds are only found in small amounts in the crude extract of B. sempervirens L., ester hydrolysis was used to increase the yield.

3.4. Spectroscopic Analysis of Isolated Compounds

NMR spectra were recorded on an Agilent DD2 600 MHz spectrometer (Agilent, Santa Clara, CA, USA) at 25 °C in CDCl₃ or CD₃OD. Spectra were referenced to the solvent signals (CDCl₃: ¹H: 7.260 ppm; ¹³C: 77.160 ppm; CD₃OD: ¹H: 3.310 ppm; and ¹³C: 49.000 ppm) and were evaluated with MestReNova version 11.0 software (Mestrelab Research, Santiago de Compostela, Spain).

UHPLC/+ESI-QqTOF-MS/MS measurements were performed as described previously [11]. The sample concentration of the crude extract was 10 mg/mL in case of the CPC fractions 1 mg/mL, and for the isolated compounds it was 0.1 mg/mL.

UV spectra of compounds 22 and 23 were recorded with a U-2900 spectrophotometer (Hitachi, Tokyo, Japan) in methanol.

3.5. Spectral Data of Isolated Buxus-Alkaloids

O-tigloylcyclovirobuxeine-B (1): previously described in [6,11].

Cyclovirobuxeine-B (2): white powder; ¹H NMR (600 MHz, CDCl₃; δ (ppm), intensity, mult., J (Hz)): 5.62 (1H, ddd, 10.6, 1.4, 1.4, H-6), 5.40 (1H, ddd, 10.6, 6.0, 3.1, H-7), 4.17 (1H, ddd, 9.2, 6.7, 2.1, H-16), 2.57 (1H, m, H-20), 2.53 (1H, dd, 5.8, 2.2, H-8), 2.47 (3H, s, H-33/34), 2.29 (6H, s, H-31/32), 2.06 (1H, m, H-3), 1.98 (1H, dd, 13.2, 9.7, H-15α), 1.86 (1H, m, H-5), 1.82 (1H, dd, 14.6, 5.7, H-11α), 1.75 (1H, m, H-2α), 1.69 (1H, td, 13.3, 5.0, H-12α), 1.63 (1H, dd, 10.5, 6.7, H-17), 1.54 (1H, m, H-2β), 1.53 (2H, m, H-1), 1.41 (1H, ddd, 15.0, 5.1, 1.9, H-11β), 1.36 (1H, m, H-12β), 1.28 (1H, m, H-15β), 1.12 (3H, d, 6.2, H-21), 1.06 (3H, s, H-29), 0.94 (3H, s, H-28), 0.91 (3H, s, H-18), 0.79 (3H, s, H-30), 0.72 (1H, d, 4.0, H-19α), -0.21 (1H, d, 4.0, H-19β);

¹³C NMR (150 MHz, CDCl₃; δ (ppm)): 128.37 (CH, C-7), 127.72 (CH, C-6), 78.70 (CH, C-16), 71.43 (CH, C-3), 61.15 (CH, C-17), 59.17 (CH, C-20), 49.86 (qC, C-14), 48.78 (CH, C-5), 45.62 (qC, C-13), 44.31 (CH₃, C-31/32), 43.37 (CH, C-8), 41.94 (CH₂, C-15), 41.60 (qC, C-4), 33.52 (CH₃, C-33/34), 32.10 (CH₂, C-12), 31.15 (CH₂, C-1), 28.86 (qC, C-10), 26.17 (CH₃, C-29), 24.96 (CH₂, C-11), 20.92 (qC, C-9), 20.03 (CH₂, C-2), 18.77 (CH₂, C-19), 18.63 (CH₃, C-21), 18.39 (CH₃, C-28), 16.66 (CH₃, C-30), 15.70 (CH₃, C-18).

+ESI-QqTOF-MS (m/z): 415.3696 [M + H]⁺, 208.1902 [M + 2H]²⁺ (calcd for C₂₇H₄₇N₂O⁺: 415.3688, for C₂₇H₄₈N₂O²⁺: 208.1884).

O-tigloylcyclomicrophylline-B (3): colorless gum; ¹H NMR and ¹³C NMR (600/150 MHz, CDCl₃) see Table 2;

+ESI-QqTOF-MS (m/z): 513.4221 [M + H]⁺, 257.2174 [M + 2H]²⁺ (calcd for C₃₂H₅₃N₂O₃⁺: 513.4056, for C₃₂H₅₄N₂O₃²⁺: 257.2067).

O-tigloylcyclomicrophylline-A (4): white powder; ¹H NMR and ¹³C NMR (600/150 MHz, CD₃OD) see Table 2;

+ESI-QqTOF-MS (m/z): 527.4220 [M + H]⁺, 264.2186 [M + 2H]²⁺ (calcd for C₃₃H₅₅N₂O₃⁺: 527.4213, for C₃₃H₅₆N₂O₃²⁺: 264.2146).

Cyclomicrophylline-A (5): white powder; ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 5.51 (1H, m, H-6), 5.48 (1H, m, H-7), 4.15 (1H, ddd, 9.4, 6.8, 2.2, H-16), 3.81 (1H, d, 10.3, H-29α), 3.52 (1H, d, 10.4, H-29β), 2.76 (1H, m, H-20), 2.67 (1H, dd, 12.0, 3.5, H-3), 2.59 (1H, dd, 5.5, 2.5, H-8), 2.34 (6H, s, H-31/32), 2.29 (6H, s, H-33/34), 2.03 (1H, m, H-15α), 1.94 (1H, d, 2.6, H-5), 1.89 (1H, m, H-11α), 1.88 (1H, m, H-17), 1.81 (1H, m, H-2α), 1.72 (1H, m, H-12α), 1.65 (1H, m, H-2β), 1.61 (2H, m, H-1), 1.48 (1H, ddd, 15.1, 5.1, 1.9, H-11β), 1.37 (1H, m, H-12β), 1.19 (1H, dd, 13.6, 2.2, H-15β), 1.05 (3H, s, H-30), 0.98 (3H, s, H-28), 0.96 (3H, s, H-18), 0.93 (3H, d, 6.6, H-21), 0.78 (1H, d, 4.1, H-19α), -0.10 (1H, d, 4.1, H-19β);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 130.60 (CH, C-7), 126.75 (CH, C-6), 80.17 (CH, C-16), 73.21 (CH, C-3), 73.08 (CH₂, C-29), 63.88 (CH, C-20), 57.77 (CH, C-17), 50.93 (qC, C-14), 46.31 (qC, C-13), 45.92 (CH, C-5), 44.51 (CH, C-8), 44.50 (CH₃, C-33/34), 43.36 (qC, C-4), 42.97 (CH₃, C-31/32), 42.39 (CH₂, C-15), 32.95 (CH₂, C-12), 31.79 (CH₂, C-1), 29.16 (qC, C-10), 25.74 (CH₂, C-11), 21.91 (qC, C-9), 19.54 (CH₂, C-2), 19.24 (CH₂, C-19), 19.20 (CH₃, C-28), 15.70 (CH₃, C-18), 12.81 (CH₃, C-30), 10.53 (CH₃, C-21).

+ESI-QqTOF-MS (m/z): 445.3835 [M + H]⁺, 223.1989 [M + 2H]²⁺ (calcd for C₂₈H₄₉N₂O₂⁺: 445.3794, for C₂₈H₅₀N₂O₂²⁺: 223.1936).

Cyclomicrophyllidine-A (6): colorless gum; ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 8.00 (2H, m, H-2′/6′), 7.59 (1H, m, H-4′), 7.47 (2H, m, H-3′/5′), 5.49 (1H, m, H-6), 5.46 (1H, m, H-7), 5.34 (1H, ddd, 8.6, 5.9, 1.1, H-16), 3.80 (1H, m, H-29α), 3.51 (1H, m, H-29β), 2.66 (1H, m, H-20), 2.66 (1H, m, H-3), 2.59 (1H, dd, 5.4, 2.5, H-8), 2.35 (1H, m, H-17), 2.34 (6H, s, H-31/32), 2.16 (1H, m, H-15α), 2.09 (6H, s, H-33/34), 1.94 (1H, br s, H-5), 1.86 (1H, m, H-11α), 1.82 (1H, m, H-2α), 1.72 (1H, dd, 13.3, 5.1, H-12α), 1.64 (1H, m, H-2β), 1.61 (2H, m, H-1), 1.47 (1H, m, H-11β), 1.37 (1H, ddd, 13.1, 5.6, 1.9, H-12β), 1.24 (1H, d(d), 14.2, (<1), H-15β), 1.05 (3H, s, H-30), 1.04 (3H, s, H-28), 0.96 (3H, s, H-18), 0.90 (3H, d, 6.4, H-21), 0.78 (1H, d, 4.1, H-19α), -0.10 (1H, d, 4.1, H-19β);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 167.64 (qC, OCO), 134.21 (CH, C-4′), 132.17 (qC, C-1′), 130.60 (CH, C-7), 130.32 (CH, C-2′/6′), 129.58 (CH, C-3′/5′), 126.75 (CH, C-6), 81.87 (CH, C-16), 73.19 (CH, C-3), 73.11 (CH₂, C-29), 61.36 (CH, C-20), 56.95 (CH, C-17), 50.93 (qC, C-14), 46.28 (qC, C-13), 45.93 (CH, C-5), 44.51 (CH, C-8), 43.36 (qC, C-4), 43.27 (CH₂, C-15), 42.98 (CH₃, C-31/32), 40.77 (CH₃, C-33/34), 32.95 (CH₂, C-12), 31.80 (CH₂, C-1), 29.17 (qC, C-10), 25.74 (CH₂, C-11), 21.91 (qC, C-9), 19.53 (CH₂, C-2), 19.25 (CH₂, C-19), 18.30 (CH₃, C-28), 15.70 (CH₃, C-18), 12.81 (CH₃, C-30), 10.49 (CH₃, C-21).

+ESI-QqTOF-MS (m/z): 549.4043 [M + H]⁺, 275.2089 [M + 2H]²⁺ (calcd for C₃₅H₅₃N₂O₃⁺: 549.4056, for C₃₅H₅₄N₂O₃²⁺: 275.2067).

Cyclomicrophyllidine-B (7): colorless gum; ¹H NMR and ¹³C NMR (600/150 MHz, CD₃OD) see Table 2;

+ESI-QqTOF-MS (m/z): 535.3964 [M + H]⁺, 268.2029 [M + 2H]²⁺ (calcd for C₃₄H₅₁N₂O₃⁺: 535.3900, for C₃₄H₅₂N₂O₃²⁺: 268.1989).

O-benzoyl-cycloprotobuxoline-D (8): colorless gum; ¹H NMR and ¹³C NMR (600/150 MHz, CD₃OD) see Table 2;

+ESI-QqTOF-MS (m/z): 507.4024 [M + H]⁺, 254.2062 [M + 2H]²⁺ (calcd for C₃₃H₅₁N₂O₂⁺: 507.7830, for C₃₃H₅₂N₂O₂²⁺: 254.3955).

N-benzoyl-O-acetyl-cycloxo-buxoline-F (9): colorless gum; ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 7.75 (2H, m, H-2′/6′), 7.53 (1H, m, H-4′), 7.46 (2H, m, H-3′/5′), 4.36 (1H, dd, 12.7, 4.3, H-3), 3.90 (1H, m, H-29α), 3.77 (1H, d, 11.6, H-29β), 3.42 (1H, m, H-20), 2.91 (3H, s, H-33/34), 2.75 (3H, s, H-33/34), 2.66 (1H, s, H-12α), 2.47 (1H, m, H-1α), 2.40 (1H, m, H-12β), 2.38 (1H, m, H-17), 2.20 (1H, m, H-8), 2.10 (1H, m, H-5), 2.09 (3H, s, Ac-CH₃), 2.06 (1H, m, H-16α), 1.86 (1H, dd, 13.1, 4.0, H-2α), 1.73 (1H, m, H-15α), 1.72 (1H, m, H-2β), 1.67 (1H, m, H-15β), 1.66 (1H, m, H-16β), 1.62 (1H, m, H-7α), 1.60 (1H, d, 3.9, H-19α), 1.56 (1H, dd, 13.3, 3.9, H-6α), 1.42 (1H, m, H-7β), 1.37 (1H, m, H-1β), 1.29 (3H, d, 6.6, H-21), 1.26 (1H, d, 3.9, H-19β), 1.15 (1H, m, H-6β), 1.14 (3H, s, H-28), 0.96 (3H, s, H-18), 0.90 (3H, s, H-30);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 212.85 (qC, C-11), 173.10 (qC, Ac-CO), 170.67 (qC, OCNH), 136.35 (qC, C-1′), 132.47 (CH, C-4′), 129.45 (CH, C-3′/5′), 128.42 (CH, C-2′/6′), 67.16 (CH, C-20), 66.98 (CH₂, C-29), 52.74 (CH₂, C-12), 52.42 (CH, C-3), 49.79 (qC, C-14), 48.09 (CH, C-17), 47.01 (qC, C-13), 44.37 (qC, C-4), 43.57 (CH₃, C-33/34), 42.90 (CH, C-5), 42.79 (CH, C-8), 39.29 (qC, C-10), 35.96 (CH₃, C-33/34), 35.19 (qC, C-9), 35.05 (CH₂, C-15), 32.13 (CH₂, C-19), 29.13 (CH₂, C-1), 28.33 (CH₂, C-2), 26.23 (CH₂, C-16), 25.72 (CH₂, C-7), 20.94 (CH₃, Ac-CH₃), 19.83 (CH₂, C-6), 19.34 (CH₃, C-28), 17.24 (CH₃, C-18), 11.98 (CH₃, C-30), 11.65 (CH₃, C-21).

+ESI-QqTOF-MS (m/z): 563.3939 [M + H]⁺, 282.2024 [M + 2H]²⁺ (calcd for C₃₅H₅₁N₂O₄⁺: 563.3849, for C₃₅H₅₂N₂O₄²⁺: 282.1964); MS/MS (m/z): 518 [M-(CH₃)₂NH]⁺, 476 [518-CH₂=CO]⁺, 458 [476-H₂O]⁺, 122 [C₆H₅CONH₃]⁺, 105 [C₆H₅CO]⁺.

N-benzoyl-cycloxo-buxoline-F (10): colorless gum; ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 7.83 (2H, m, H-2′/6′), 7.55 (1H, m, H-4′), 7.47 (2H, m, H-3′/5′), 4.15 (1H, dd, 12.6, 4.0, H-3), 3.41 (1H, m, H-20), 3.39 (1H, m, H-29α), 3.13 (1H, d, 12.7, H-29β), 2.91 (3H, s, H-33/34), 2.75 (3H, s, H-33/34), 2.65 (1H, m, H-12α), 2.43 (1H, m, H-1α), 2.40 (1H, m, H-12β), 2.38 (1H, m, H-17), 2.20 (1H, m, H-8), 2.09 (1H, m, H-5), 2.06 (1H, m, H-16α), 1.94 (1H, dd, 13.1, 4.0, H-2α), 1.75 (1H, m, H-2β), 1.73 (1H, m, H-15α), 1.68 (1H, m, H-6α), 1.66 (1H, m, H-15β), 1.64 (1H, m, H-16β), 1.62 (1H, m, H-7α), 1.61 (1H, d, 3.8, H-19α), 1.48 (1H, m, H-7β), 1.34 (1H, m, H-1β), 1.29 (3H, d, 5.4, H-21), 1.26 (1H, d, 3.9, H-19β), 1.14 (3H, s, H-28), 1.07 (1H, m, H-6β), 0.95 (3H, s, H-18), 0.72 (3H, s, H-30);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 212.87 (qC, C-11), 171.59 (qC, OCNH), 135.42 (qC, C-1′), 132.83 (CH, C-4′), 129.57 (CH, C-3′/5′), 128.53 (CH, C-2′/6′), 67.19 (CH, C-20), 65.18 (CH₂, C-29), 53.36 (CH, C-3), 52.78 (CH₂, C-12), 49.90 (qC, C-14), 48.09 (CH, C-17), 47.08 (qC, C-13), 45.88 (qC, C-4), 43.56 (CH₃, C-33/34), 42.79 (CH, C-5), 42.34 (CH, C-8), 39.52 (qC, C-10), 35.96 (CH₃, C-33/34), 35.42 (qC, C-9), 34.96 (CH₂, C-15), 31.65 (CH₂, C-19), 29.27 (CH₂, C-1), 27.79 (CH₂, C-2), 26.23 (CH₂, C-16), 25.46 (CH₂, C-7), 19.49 (CH₂, C-6), 19.34 (CH₃, C-28), 17.22 (CH₃, C-18), 11.90 (CH₃, C-30), 11.65 (CH₃, C-21).

+ESI-QqTOF-MS (m/z): 521.3766 [M + H]⁺, 261.1941 [M + 2H]²⁺ (calcd for C₃₃H₄₉N₂O₃⁺: 521.7660, for C₃₃H₅₀N₂O₃²⁺: 261.387); MS/MS (m/z): 476 [M-(CH₃)₂NH]⁺, 458 [476-H₂O]⁺, 122 [C₆H₅CONH₃]⁺, 105 [C₆H₅CO]⁺.

29-hydroxy-cyclomikuranine-L (11): colorless gum; ¹H NMR and ¹³C NMR (600/150 MHz, CD₃OD) see Table 3;

+ESI-QqTOF-MS (m/z): 418.3362 [M + H]⁺ (calcd for C₂₆H₄₄NO₃⁺: 418.3321).

N_b-dimethylcycloxobuxoviricine (12): white powder; ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 6.96 (1H, d, 10.1, H-1), 5.92 (1H, d, 10.1, H-2), 4.32 (1H, ddd, 9.4, 7.4, 2.1, H-16), 3.59 (1H, m, H-20), 2.96 (3H, s, H-33/34), 2.81 (3H, s, H-33/34), 2.23 (1H, dd, 11.1, 7.4, H-17), 2.15 (1H, dd, 11.1, 7.4, H-5), 2.10 (1H, m, H-11α), 2.05 (1H, m, H-15α), 2.00 (1H, dd, 10.1, 6.8, H-8), 1.88 (1H, m, H-12α), 1.67 (1H, m, H-11β), 1.62 (1H, m, H-6α), 1.62 (1H, m, H-12β), 1.56 (1H, m, H-7α), 1.44 (1H, dd, 13.8, 2.1, H-15β), 1.39 (1H, d, 4.7, H-19α), 1.32 (3H, d, 6.6, H-21), 1.30 (1H, m, H-7β), 1.21 (3H, s, H-28), 1.16 (1H, dd, 12.8, 4.0, H-6β), 1.09 (3H, s, H-29), 1.08 (3H, s, H-18), 0.97 (3H, s, H-30), 0.88 (1H, d, 4.7, H-19β);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 207.60 (qC, C-3), 156.58 (CH, C-1), 127.19 (CH, C-2), 76.92 (CH, C-16), 68.12 (CH, C-20), 56.08 (CH, C-17), 49.38 (qC, C-14), 47.40 (qC, C-13), 47.18 (qC, C-4), 46.97 (CH₂, C-15), 46.06 (CH, C-5), 45.31 (CH, C-8), 43.69 (CH₃, C-33/34), 36.55 (CH₃, C-33/34), 32.33 (CH₂, C-12), 31.41 (qC, C-10), 30.88 (CH₂, C-19), 28.15 (CH₂, C-11), 25.41 (qC, C-9), 24.88 (CH₂, C-7), 21.86 (CH₃, C-29), 20.61 (CH₂, C-6), 20.50 (CH₃, C-28), 19.62 (CH₃, C-30), 18.48 (CH₃, C-18), 11.48 (CH₃, C-21).

+ESI-QqTOF-MS (m/z): 400.3291 [M + H]⁺ (calcd for C₂₆H₄₂NO₂⁺: 400.3216).

(E)-cyclobuxophyllinine-M (13) and (Z)-cyclobuxophyllinine-M (14) (93.5%:6.5%): white powder; ¹H NMR (600 MHz, CDCl₃; δ (ppm), intensity, mult., J (Hz)): 6.58 (1H, q, 7.5, H-20 (E)), 5.74 (1H, q, 7.4, H-20 (Z)), 2.75 (3H, s, H-31/32), 2.64 (1H, m, H-3), 2.19 (1H, dd, 17.2, 1.5, H-15α), 2.11 (1H, m, H-11α), 2.08 (1H, m, H-12α), 2.06 (1H, m, H-12β), 2.04 (1H, m, H-2α), 2.01 (1H, m, H-15β), 1.87 (1H, m, H-2β), 1.84 (3H, d, 7.6, H-21), 1.68 (1H, m, H-6α), 1.66 (1H, m, H-8), 1.57 (1H, m, H-1α), 1.43 (1H, m, H-1β), 1.41 (1H, m, H-5), 1.38 (1H, m, H-7α), 1.33 (3H, s, H-18), 1.29 (1H, m, H-11β), 1.16 (3H, s, H-29), 1.11 (1H, qd, 12.6, 2.5, H-7β), 0.98 (3H, s, H-30), 0.94 (3H, s, H-28), 0.84 (1H, qd, 12.7, 2.4, H-6β), 0.67 (1H, d, 4.6, H-19α), 0.49 (1H, d, 4.6, H-19β);

¹³C NMR (150 MHz, CDCl₃; δ (ppm)): 206.60 (qC, C-16), 146.59 (qC, C-17), 132.23 (CH, C-20 (Z)), 130.62 (CH, C-20 (E)), 69.81 (CH, C-3), 49.43 (CH₂, C-15), 48.07 (CH, C-5), 46.76 (qC, C-13), 45.78 (CH, C-8), 42.48 (qC, C-14), 39.42 (qC, C-4), 32.87 (CH₃, C-31/32), 31.84 (CH₂, C-1), 30.27 (CH₂, C-19), 29.36 (CH₂, C-12), 26.20 (CH₂, C-7), 26.12 (qC, C-10), 26.04 (CH₂, C-11), 25.36 (CH₃, C-29), 24.40 (CH₃, C-18), 23.73 (CH₂, C-2), 21.03 (CH₃, C-28), 20.89 (CH₂, C-6), 19.88 (qC, C-9), 15.02 (CH₃, C-30), 13.39 (CH₃, C-21).

+ESI-QqTOF-MS (m/z): 370.3182 [M + H]⁺ (calcd for C₂₅H₄₀NO⁺: 370.3110).

(E)-cyclosuffrobuxinine-M (15) and (Z)-cyclosuffrobuxinine-M (16) (69.9%:30.1%): light yellow gum; ¹H NMR (600 MHz, CDCl₃; δ (ppm), intensity, mult., J (Hz)): 6.63 (1H, q, 7.5, H-20 (E)), 5.78 (1H, q, 7.3, H-20 (Z)), 4.92 (1H, s, H-29α), 4.87 (1H, s, H-29β), 3.56 (1H, m, H-3), 2.85 (3H, s, H-31/32), 2.32 (1H, m, H-2α), 2.26 (1H, m, H-15α (Z)), 2.23 (1H, m, H-15α (E)), 2.20 (1H, m, H-11α (E)), 2.15 (1H, d, 4.2, H-5), 2.12 (3H, d, 7.4, H-21 (Z)), 2.10 (1H, m, H-11α (Z)), 2.10 (2H, m, H-12α (E)), 2.06 (1H, m, H-15β (E)), 2.03 (1H, m, H-15β (Z)), 1.85 (3H, d, 7.5, H-21 (E)), 1.81 (1H, m, H-1α), 1.75 (1H, dd, 12.4, 4.7, H-8), 1.72 (1H, m, H-12β (Z)), 1.60 (1H, m, H-2β), 1.57 (1H, m, H-6α), 1.51 (1H, m, H-1β), 1.42 (1H, m, H-7α), 1.37 (1H, m, H-11β), 1.33 (3H, s, H-18 (E)), 1.25 (3H, s, H-18 (Z)), 1.19 (1H, dd, 12.6, 2.3, H-7β), 1.09 (1H, qd, 12.7, 2.3, H-6β), 0.98 (3H, s, H-28 (E)), 0.95 (3H, s, H-28 (Z)), 0.44 (1H, d, 4.5, H-19α), 0.22 (1H, d, 4.7, H-19β (E)), 0.19 (1H, d, 4.8, H-19β (Z));

¹³C NMR (150 MHz, CDCl₃; δ (ppm)): 209.46 (qC, C-16 (Z)), 207.28 (qC, C-16 (E)), 146.72 (qC, C-17 (Z)), 146.51 (qC, C-4 (Z)), 146.46 (qC, C-4 (E)), 146.45 (qC, C-17 (E)), 132.91 (CH, C-20 (Z)), 131.46 (CH, C-20 (E)), 104.37 (CH₂, C-29 (Z)), 104.36 (CH₂, C-29 (E)), 62.83 (CH, C-3 (Z)), 62.81 (CH, C-3 (E)), 50.76 (CH₂, C-15 (Z)), 49.30 (CH₂, C-15 (E)), 46.84 (qC, C-13 (E)), 46.74 (qC, C-13 (Z)), 45.40 (CH, C-8 (E)), 45.38 (CH, C-8 (Z)), 44.26 (CH, C-5 (E)), 44.18 (CH, C-5 (Z)), 42.58 (qC, C-14 (E)), 42.11 (qC, C-14 (Z)), 31.79 (CH₃, C-31/32 (Z)), 31.77 (CH₃, C-31/32 (E)), 31.65 (qC, C-10), 31.03 (CH₂, C-1 (E)), 30.95 (CH₂, C-1 (Z)), 30.66 (CH₂, C-2), 29.32 (CH₂, C-12 (E)), 28.50 (CH₂, C-12 (Z)), 27.92 (CH₂, C-19 (E)), 27.83 (CH₂, C-19 (Z)), 26.65 (CH₂, C-11 (E)), 26.48 (CH₂, C-11 (Z)), 26.40 (CH₃, C-18 (Z)), 25.35 (CH₂, C-7 (E)), 25.25 (CH₂, C-7 (Z)), 24.30 (CH₃, C-18 (E)), 23.55 (qC, C-9 (Z)), 23.41 (qC, C-9 (E)), 23.24 (CH₂, C-6 (E)), 23.14 (CH₂, C-6 (Z)), 20.99 (CH₃, C-28 (E)), 20.59 (CH₃, C-28 (Z)), 14.40 (CH₃, C-21 (Z)), 13.46 (CH₃, C-21 (E)).

+ESI-QqTOF-MS (m/z): 354.2848 [M + H]⁺ (calcd for C₂₄H₃₆NO⁺: 354.2797).

Cyclomicrobuxinine (17): light yellow powder; ¹H NMR (600 MHz, CDCl₃; δ (ppm), intensity, mult., J (Hz)): 4.90 (1H, ddd, 9.5, 6.6, 2.0, H-16), 4.85 (1H, s, H-29α), 4.61 (1H, s, H-29β), 3.02 (1H, d, 6.6, H-17), 2.95 (1H, dd, 11.8, 4.2, H-3), 2.53 (3H, s, H-31/32), 2.19 (1H, m, H-11α), 2.17 (1H, m, H-2α), 2.15 (3H, s, H-21), 2.10 (1H, m, H-5), 2.02 (1H, m, H-12α), 1.94 (1H, m, H-15α), 1.76 (1H, m, H-1α), 1.71 (1H, m, H-12β), 1.54 (1H, m, H-8), 1.51 (1H, m, H-6α), 1.43 (1H, dd, 13.9, 2.0, H-15β), 1.36 (1H, m, H-7α), 1.34 (1H, m, H-1β), 1.26 (1H, m, H-11β), 1.23 (1H, m, H-2β), 1.21 (3H, s, H-28), 1.17 (1H, m, H-7β), 1.04 (1H, m, H-6β), 0.90 (3H, s, H-18), 0.31 (1H, d, 4.4, H-19α), 0.07 (1H, d, 4.5, H-19β);

¹³C NMR (150 MHz, CDCl₃; δ (ppm)): 209.61 (qC, C-20), 153.08 (qC, C-4), 101.59 (CH₂, C-29), 72.04 (CH, C-16), 70.66 (CH, C-17), 63.65 (CH, C-3), 48.51 (qC, C-14), 47.77 (qC, C-13), 47.28 (CH, C-8), 45.93 (CH₂, C-15), 44.34 (CH, C-5), 34.39 (CH₃, C-31/32), 34.27 (CH₂, C-2), 32.44 (qC, C-10), 31.90 (CH₂, C-1), 31.54 (CH₂, C-12), 31.37 (CH₃, C-21), 27.81 (CH₂, C-19), 26.87 (CH₂, C-11), 25.52 (CH₂, C-7), 23.68 (CH₂, C-6), 22.85 (qC, C-9), 20.75 (CH₃, C-18), 20.71 (CH₃, C-28).

+ESI-QqTOF-MS (m/z): 372.2963 [M + H]⁺ (calcd for C₂₄H₃₈NO₂⁺: 372.2903).

Cyclomicrobuxine (18): light yellow powder; ¹H NMR (600 MHz, CDCl₃; δ (ppm), intensity, mult., J (Hz)): 5.07 (1H, s, H-29α), 4.90 (1H, m, H-16), 4.75 (1H, s, H-29β), 3.02 (1H, d, 6.7, H-17), 2.96 (1H, m, H-3), 2.49 (6H, br s, H-31/32), 2.19 (1H, m, H-11α), 2.16 (3H, s, H-21), 2.09 (1H, m, H-5), 2.06 (1H, m, H-2α), 2.02 (1H, m, H-12α), 1.94 (1H, m, H-15α), 1.72 (1H, m, H-12β), 1.57 (1H, m, H-6α), 1.54 (1H, dd, 12.1, 4.7, H-8), 1.44 (1H, m, H-15β), 1.43 (1H, m, H-1α), 1.42 (1H, m, H-2β), 1.36 (1H, m, H-7α), 1.27 (1H, m, H-1β), 1.26 (1H, m, H-11β), 1.21 (3H, s, H-28), 1.19 (1H, m, H-7β), 1.02 (1H, m, H-6β), 0.92 (3H, s, H-18), 0.33 (1H, d, 4.5, H-19α), 0.08 (1H, d, 4.5, H-19β);

¹³C NMR (150 MHz, CDCl₃; δ (ppm)): 209.53 (qC, C-20), 152.64 (qC, C-4), 104.62 (CH₂, C-29), 72.08 (CH, C-16), 70.63 (CH, C-17), 68.64 (CH, C-3), 48.49 (qC, C-14), 47.76 (qC, C-13), 47.29 (CH, C-8), 45.94 (CH₂, C-15), 44.52 (CH, C-5), 42.47 (CH₃, C-31/32), 32.08 (qC, C-10), 31.93 (CH₂, C-1), 31.51 (CH₂, C-12), 31.37 (CH₃, C-21), 27.10 (CH₂, C-2), 27.76 (CH₂, C-19), 26.90 (CH₂, C-11), 25.53 (CH₂, C-7), 23.86 (CH₂, C-6), 22.78 (qC, C-9), 20.75 (CH₃, C-18), 20.74 (CH₃, C-28).

+ESI-QqTOF-MS (m/z): 386.3094 [M + H]⁺ (calcd for C₂₅H₄₀NO₂⁺: 386.3059).

Irehine (19): light yellow powder; ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 5.34 (1H, m, H-6), 3.40 (1H, m, H-3), 3.35 (1H, m, H-20), 2.87 (3H, s, H-33/34), 2.70 (3H, s, H-33/34), 2.24 (1H, m, H-4α), 2.21 (1H, m, H-4β), 2.04 (1H, m, H-7α), 2.00 (1H, m, H-7β), 1.98 (1H, m, H-12α), 1.91 (1H, m, H-16α), 1.88 (1H, m, H-1α), 1.81 (1H, m, H-15α), 1.79 (1H, m, H-2α), 1.69 (1H, m, H-17), 1.62 (1H, m, H-11α), 1.55 (1H, m, H-16β), 1.54 (1H, m, H-8), 1.51 (1H, m, H-11β), 1.49 (1H, m, H-2β), 1.33 (1H, m, H-12β), 1.33 (3H, d, 6.6, H-21), 1.31 (1H, m, H-15β), 1.20 (1H, m, H-14), 1.08 (1H, m, H-1β), 1.04 (3H, s, H-19), 1.00 (1H, m, H-9), 0.79 (3H, s, H-18);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 142.33 (qC, C-5), 122.12 (CH, C-6), 72.36 (CH, C-3), 67.01 (CH, C-20), 57.58 (CH, C-14), 53.13 (CH, C-17), 51.41 (CH, C-9), 43.99 (qC, C-13), 43.36 (CH₃, C-33/34), 42.95 (CH₂, C-4), 38.51 (CH₂, C-1), 37.64 (qC, C-10), 35.73 (CH₃, C-33/34), 33.08 (CH, C-8), 32.81 (CH₂, C-7), 32.25 (CH₂, C-2), 29.36 (CH₂, C-12), 26.83 (CH₂, C-16), 25.28 (CH₂, C-15), 22.04 (CH₂, C-11), 19.82 (CH₃, C-19), 12.26 (CH₃, C-18), 11.96 (CH₃, C-21).

+ESI-QqTOF-MS (m/z): 346.3215 [M + H]⁺ (calcd for C₂₃H₄₀NO⁺: 346.3110).

16-α-hydroxybuxaminone (20): light yellow powder; ¹H NMR (600 MHz, CDCl₃; δ (ppm), intensity, mult., J (Hz)): 5.99 (1H, s, H-19), 5.63 (1H, br s, H-11), 4.93 (1H, m, H-16), 3.02 (1H, dd, 12.9, 4.0, H-3), 2.99 (1H, d, 6.6, H-17), 2.94 (3H, s, H-31/32), 2.79 (3H, s, H-31/32), 2.52 (1H, d, 18.4, H-12α), 2.43 (1H, m, H-1α), 2.24 (1H, m, H-1β), 2.20 (1H, m, H-6α), 2.17 (3H, s, H-21), 2.12 (1H, m, H-12β), 2.07 (1H, m, H-5), 2.05 (1H, m, H-15α), 2.02 (1H, m, H-8), 1.95 (1H, m, H-2α), 1.83 (1H, m, H-2β), 1.53 (1H, m, H-7α), 1.49 (1H, dd, 13.8, 1.9, H-15β), 1.40 (1H, m, H-6β), 1.35 (3H, s, H-29), 1.31 (1H, m, H-7β), 0.96 (3H, s, H-30), 0.95 (3H, s, H-28), 0.68 (3H, s, H-18);

¹³C NMR (150 MHz, CDCl₃; δ (ppm)): 209.07 (qC, C-20), 138.03 (qC, C-9), 131.99 (qC, C-10), 131.05 (CH, C-19), 129.94 (CH, C-11), 76.34 (CH, C-3), 71.76 (CH, C-16), 69.03 (CH, C-17), 51.77 (CH, C-5), 48.94 (CH, C-8), 48.15 (qC, C-14), 47.12 (CH₃, C-31/32), 45.78 (qC, C-13), 43.66 (CH₂, C-15), 41.41 (qC, C-4), 40.47 (CH₃, C-31/32), 39.41 (CH₂, C-1), 37.36 (CH₂, C-12), 31.23 (CH₃, C-21), 29.53 (CH₂, C-6), 25.31 (CH₂, C-7), 24.24 (CH₃, C-29), 23.45 (CH₂, C-2), 18.45 (CH₃, C-18), 18.36 (CH₃, C-28), 15.13 (CH₃, C-30).

+ESI-QqTOF-MS (m/z): 400.3287 [M + H]⁺ (calcd for C₂₆H₄₂NO₂⁺: 400.3216).

N₂₀-acetylbuxamine-E (21): colorless gum; ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 6.05 (1H, s, H-19), 5.61 (1H, br s, H-11), 3.92 (1H, m, H-20), 3.29 (1H, m, H-3), 2.97 (3H, s, H-31/32), 2.79 (3H, s, H-31/32), 2.41 (1H, m, H-1α), 2.27 (1H, m, H-1β), 2.21 (1H, m, H-5), 2.21 (1H, m, H-7α), 2.18 (1H, m, H-12α), 2.14 (1H, m, H-8), 2.08 (1H, m, H-12β), 2.06 (1H, m, H-2α), 1.92 (1H, m, H-16α), 1.91 (1H, m, H-17), 1.90 (3H, s, Ac-CH₃), 1.84 (1H, m, H-2β), 1.59 (1H, m, H-6α), 1.50 (1H, dd, 12.0, 6.2, H-15α), 1.45 (1H, m, H-15β), 1.42 (1H, m, H-16β), 1.32 (1H, m, H-6β), 1.29 (1H, m, H-7β), 1.20 (3H, s, H-29), 1.10 (3H, d, 6.4, H-21), 0.91 (3H, s, H-30), 0.81 (3H, s, H-18), 0.74 (3H, s, H-28);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 171.86 (qC, Ac-CO), 139.24 (qC, C-9), 133.06 (qC, C-10), 131.85 (CH, C-19), 131.62 (CH, C-11), 77.22 (CH, C-3), 52.26 (CH, C-17), 52.04 (CH, C-5), 50.73 (CH, C-8), 49.84 (qC, C-14), 49.55 (CH, C-20), 47.24 (CH₃, C-31/32), 44.22 (qC, C-13), 41.93 (qC, C-4), 40.87 (CH₃, C-31/32), 40.08 (CH₂, C-1), 39.21 (CH₂, C-12), 33.88 (CH₂, C-15), 30.73 (CH₂, C-7), 27.45 (CH₂, C-16), 26.27 (CH₂, C-6), 24.22 (CH₂, C-2), 23.78 (CH₃, C-29), 22.67 (CH₃, Ac-CH₃), 21.18 (CH₃, C-21), 17.38 (CH₃, C-28), 16.13 (CH₃, C-18), 15.07 (CH₃, C-30).

+ESI-QqTOF-MS (m/z): 427.3719 [M + H]⁺, 214.1903 [M + 2H]²⁺ (calcd for C₂₈H₄₇N₂O⁺: 427.3688, for C₂₈H₄₈N₂O²⁺: 214.1884); MS/MS (m/z): 382 [M-(CH₃)₂NH]⁺, 340 [382-CH₂=CO]⁺, 323 [340-NH₃]⁺.

N-benzoyl-O-acetylbuxodienine-E (22): white powder; UV (MeOH; λmax, (log ε)): 237 (4.54), 245 (4.53), 253 (4.35); ¹H NMR (600 MHz, CD₃OD; δ (ppm), intensity, mult., J (Hz)): 7.79 (2H, m, H-2′/6′), 7.51 (1H, m, H-4′), 7.45 (2H, m, H-3′/5′), 5.94 (1H, br s, H-19), 5.55 (1H, br m, H-11), 5.06 (1H, ddd, 9.0, 6.6, 1.4, H-16), 4.43 (1H, m, H-20), 2.37 (1H, m, H-17), 2.35 (1H, m, H-12α), 2.30 (6H, s, H-31/32), 2.30 (1H, m, H-1α), 2.22 (1H, m, H-3), 2.15 (1H, m, H-6α), 2.13 (1H, m, H-1β), 2.13 (1H, m, H-12β), 2.13 (1H, m, H-15α), 2.10 (1H, m, H-8), 2.01 (1H, m, H-5), 1.80 (1H, dd, 12.0, 3.4, H-2α), 1.62 (3H, s, Ac-CH₃), 1.55 (1H, qd, 14.1, 5.5, H-2β), 1.47 (1H, m, H-7α), 1.42 (1H, m, H-6β), 1.35 (1H, dd, 14.3, 1.5, H-15β), 1.30 (1H, m, H-7β), 1.28 (3H, d, 6.7, H-21), 1.03 (3H, s, H-29), 0.92 (3H, s, H-18), 0.89 (3H, s, H-28), 0.74 (3H, s, H-30);

¹³C NMR (150 MHz, CD₃OD; δ (ppm)): 172.39 (qC, Ac-CO), 168.63 (qC, OCNH), 139.68 (qC, C-9), 137.46 (qC, C-10), 135.84 (qC, C-1′), 132.55 (CH, C-4′), 129.65 (CH, C-19), 129.46 (CH, C-3′/5′), 129.13 (CH, C-11), 128.28 (CH, C-2′/6′), 80.75 (CH, C-16), 73.14 (CH, C-3), 57.90 (CH, C-17), 53.15 (CH, C-5), 50.43 (CH, C-8), 48.31 (qC, C-14), 48.17 (CH, C-20), 44.86 (qC, C-13), 44.79 (CH₃, C-31/32), 44.12 (qC, C-4), 43.79 (CH₂, C-15), 42.26 (CH₂, C-1), 38.88 (CH₂, C-12), 31.18 (CH₂, C-6), 26.63 (CH₂, C-7), 25.29 (CH₃, C-29), 24.19 (CH₂, C-2), 20.96 (CH₃, Ac-CH₃), 20.68 (CH₃, C-21), 17.89 (CH₃, C-28), 17.02 (CH₃, C-18), 15.46 (CH₃, C-30).

+ESI-QqTOF-MS (m/z): 547.3977 [M + H]⁺, 274.2040 [M + 2H]²⁺ (calcd for C₃₅H₅₁N₂O₃⁺: 547.3900, for C₃₅H₅₂N₂O₃²⁺: 274.1989); MS/MS (m/z): 442 [M-((CH₃)₂NH)-(CH₃COOH)]⁺, 321 [442-C₇H₇NO]⁺, 148 [C₉H₁₀NO]⁺, 105 [C₇H₅O]⁺.

N-benzoyl-O-acetylbuxadine-E (23): white powder; UV (MeOH; λmax, (log ε)): 225 (4.01); ¹H NMR and ¹³C NMR (600/150 MHz, CD₃OD) see Table 3;

+ESI-QqTOF-MS (m/z): 1093.7853 [2M + H]⁺, 547.3917 [M + H]⁺, 274.2038 [M + 2H]²⁺ (calcd for C₃₅H₅₁N₂O₃⁺: 547.3900, for C₃₅H₅₂N₂O₃²⁺: 274.1989); MS/MS (m/z): 442 [M-((CH₃)₂NH)-(CH₃COOH)]⁺, 321 [442-C₇H₇NO]⁺, 148 [C₉H₁₀NO]⁺, 105 [C₇H₅O]⁺ (fragmentation pathway reported in Figure S122, Supplementary Materials).

N₂₀-acetylbuxadine-G (24): colorless gum; ¹H NMR and ¹³C NMR (600/150 MHz, CDCl₃) see Table 3;

+ESI-QqTOF-MS (m/z): 413.0273 [M + H]⁺, 207.4721 [M + 2H]²⁺ (calcd for C₂₇H₄₅N₂O⁺: 413.3532, for C₂₇H₄₆N₂O²⁺: 207.1805); MS/MS (m/z): 382 [M-CH₃NH₂]⁺, 323 [382-CH₃CONH₂]⁺.

17,20-dihydroxybuxadine-M (25): colorless gum; ¹H NMR and ¹³C NMR (600/150 MHz, CDCl₃) see Table 3;

+ESI-QqTOF-MS (m/z): 388.3272 [M + H]⁺ (calcd for C₂₅H₄₂NO₂⁺: 388.3216); MS/MS (m/z): 339 [M-(CH₃NH₂)-(H₂O)]⁺, 321 [339-H₂O]⁺.

3.6. In Vitro Bioassays

In vitro assays for the bioactivity of the isolated Buxus-alkaloids against Tbr (bloodstream trypomastigotes, STIB 900 strain), Trypanosoma cruzi (Tc) (amastigotes, Tulahuen C4 strain), Leishmania donovani (Ldo) (amastigotes, MHOM-ET-67/L82 strain) and Pf (intraerythrocytic forms, NF54 strain), and cytotoxicity tests against mammalian cells (L6-cell line from rat-skeletal myoblasts), were performed at the Swiss Tropical and Public Health Institute (Swiss TPH, Basel, Switzerland) according to established standard protocols [36]. The alkaloids were inactive against Tc and Ldo at the concentration tested. Such a pattern of activity was also observed in other studies [37].

4. Conclusions

The present study provides an extended chemical analysis of alkaloids isolated from a B. sempervirens L. leaf extract. The structure of eight new natural products could be elucidated and the NMR data of already known Buxus-alkaloids are reported here in full for the first time. Moreover, cyclomicrophyllidine-A (6) was primarily obtained from the leaves of B. sempervirens L. Several of the isolated compounds displayed promising and selective in vitro activity against the protozoan parasites Pf and Tbr. Of the 25 structures isolated, five compounds (3, 4, 6–8) showed auspicious antiplasmodial activity with IC₅₀ values of <1.0 μM. Against the causative agent of HAT, compound 2, 6, 8, and 24 exhibited interesting IC₅₀ values in the range of 1.1–1.5 µM. The new natural product O-benzoyl-cycloprotobuxoline-D (8) was the most active substance in both cases. The highest selectivity was reached by cyclomicrophyllidine-B (7) (SI 145 for Pf) and cyclomicrophylline-A (5) (SI 42 for Tbr), respectively. Accordingly, these Buxus-alkaloids have the potential to serve as antiprotozoal lead structures. Structure-activity relationship studies are in progress in order to identify structural functionalities that increase activity and reduce toxicity. In conclusion, the work presented here may represent an important first step in the development of this new class of antiprotozoal drugs against malaria and HAT.

Supplementary Materials

The following are available online at https://0-www-mdpi-com.brum.beds.ac.uk/article/10.3390/antibiotics10060696/s1, the ¹H and ¹³C NMR spectra of all the isolated compounds are provided as Supplementary Figures S1–S4, S8–S11, S21–S24, S31–S38, S42–S45, S54–S57, S63–S70, S74–S77, S82–S118, S124–S127, S137–S140, and S149–S152. For the new natural products, additional LC/MS chromatograms, UV, and 2D NMR spectra, as well as key correlations of HMBC and COSY spectra, are supplied as Supplementary Figures S5–S7, S12–S20, S25–S30, S39–S41, S46–S53, S58–S62, S71–S73, S78–S81, S119–S123, S128–S136, S141–S148, and S153–158.

Author Contributions

Conceptualization, T.J.S.; investigation, L.U.S. and M.K.; resources, T.J.S. and P.M.; data curation, L.U.S., T.J.S. and M.K.; writing—original draft preparation, L.U.S. and T.J.S.; writing—review and editing, L.U.S., T.J.S., M.K. and P.M.; supervision, T.J.S.; project administration, T.J.S. and P.M.; funding acquisition, L.U.S. and T.J.S. All authors have read and agreed to the published version of the manuscript.

Funding

This research received external funding in the form of a doctoral fellowship for L. U. Szabó from Apothekerstiftung Westfalen-Lippe.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data is contained within the article and Supplementary Materials. The underlying raw data are available from the corresponding author on request.

Acknowledgments

L.U.S. is most grateful for financial support by Apothekerstiftung Westfalen-Lippe in the form of a doctoral fellowship. The authors thank C. O. Nnadi (Münster) for isolation of compound 23. Thanks are due to J. Sendker and F. M. Jürgens (Münster) for support with the UHPLC/+ESI-QqTOF-MS/MS analyses, to J. Köhler (Münster) for NMR measurements, and to K. Possart (Münster) for support with the spectrophotometer. We thank M. Cal, S. Keller-Maerki and R. Rocchetti for assistance with the parasite and cytotoxicity assays. This work is part of the activities of the Research Network Natural Products against Neglected Diseases (ResNet NPND, see www.resnetnpnd.org).

Conflicts of Interest

The authors declare no conflict of interest.

References

Neves, J.M.; Matos, C.; Moutinho, C.; Queiroz, G.; Gomes, L.R. Ethnopharmacological notes about ancient uses of medicinal plants in Trás-os-Montes (northern of Portugal). J. Ethnopharmacol. 2009, 124, 270–283. [Google Scholar] [CrossRef] [PubMed]
Leporatti, M.L.; Pavesi, A.; Posocco, E. Phytotherapy in the Valnerina Marche (Central Italy). J. Ethnopharmacol. 1985, 14, 53–63. [Google Scholar] [CrossRef]
Atta-ur-Rahman; Choudhary, M.I. Diterpenoid and steroidal alkaloids. Nat. Prod. Rep. 1999, 16, 619–635. [Google Scholar] [CrossRef]
Ata, A.; Andersh, B.J. Chapter 3 Buxus Steroidal Alkaloids: Chemistry and Biology; The Alkaloids: Chemistry and Biology; Academic Press: London, UK, 2008; pp. 191–213. [Google Scholar]
Yan, Y.-X.; Sun, Y.; Li, Z.-R.; Zhou, L.; Qiu, M.-H. Chemistry and Biological Activities of Buxus Alkaloids. CBC 2011, 7, 47–64. [Google Scholar] [CrossRef]
Althaus, J.B.; Jerz, G.; Winterhalter, P.; Kaiser, M.; Brun, R.; Schmidt, T.J. Antiprotozoal activity of Buxus sempervirens and activity-guided isolation of O-tigloylcyclovirobuxeine-B as the main constituent active against Plasmodium falciparum. Molecules 2014, 19, 6184–6201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Cai, S.; Risinger, A.L.; Nair, S.; Peng, J.; Anderson, T.J.C.; Du, L.; Powell, D.R.; Mooberry, S.L.; Cichewicz, R.H. Identification of Compounds with Efficacy against Malaria Parasites from Common North American Plants. J. Nat. Prod. 2016, 79, 490–498. [Google Scholar] [CrossRef] [Green Version]
Flittner, D.; Kaiser, M.; Mäser, P.; Lopes, N.P.; Schmidt, T.J. The Alkaloid-Enriched Fraction of Pachysandra terminalis (Buxaceae) Shows Prominent Activity against Trypanosoma brucei rhodesiense. Molecules 2021, 26, 591. [Google Scholar] [CrossRef] [PubMed]
Nnadi, C.O.; Althaus, J.B.; Nwodo, N.J.; Schmidt, T.J. A 3D-QSAR Study on the Antitrypanosomal and Cytotoxic Activities of Steroid Alkaloids by Comparative Molecular Field Analysis. Molecules 2018, 23, 1113. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Kupchan, S.M.; Kennedy, R.M.; Schleigh, W.R.; Ohta, G. Buxus alkaloids—XII. Tetrahedron 1967, 23, 4563–4586. [Google Scholar] [CrossRef]
Szabó, L.U.; Schmidt, T.J. Target-Guided Isolation of O-tigloylcyclovirobuxeine -B from Buxus sempervirens L. by Centrifugal Partition Chromatography. Molecules 2020, 25, 4804. [Google Scholar] [CrossRef]
Kupchan, S.M.; Ohta, G. Buxus Alkaloids. X. 1 The Isolation and Constitution of Cyclovirobuxeine-B. J. Org. Chem. 1966, 31, 608–610. [Google Scholar] [CrossRef]
Nakano, T.; Terao, S. Buxus alkaloids. Part, I. The structures of three new alkaloids, cyclomicrophylline-A., B., and C., from B. microphylla Sieb. et Zucc. Tetrahedron Lett. 1964, 5, 1035–1043. [Google Scholar] [CrossRef]
Atta-ur-Rahman; Ahmed, D.; Asif, E.; Ahmad, S.; Sener, B.; Turkoz, S. Chemical Constituents of Buxus sempervirens. J. Nat. Prod. 1991, 54, 79–82. [Google Scholar] [CrossRef]
Nakano, T.; Terao, S. Buxus alkaloids. IV. Isolation and structure elucidation of eight new alkaloids, cyclomicrophylline-A, -B, and -C, dihydrocyclomicrophylline-A and -F, cyclomicrophyllidine-A, dihydrocyclomicrophyllidine-A, and cyclomicrobuxine, from B. microphylla Sieb. et Zucc. var. suffruticosa Makino. J. Chem. Soc. Perkin Trans. 1965, 1, 4512–4537. [Google Scholar]
Leuthardt, F.L.G.; Glauser, G.; Baur, B. Composition of alkaloids in different box tree varieties and their uptake by the box tree moth Cydalima perspectalis. Chemoecology 2013, 23, 203–212. [Google Scholar] [CrossRef] [Green Version]
Choudhary, M.I.; Shahnaz, S.; Parveen, S.; Khalid, A.; Mesaik, M.A.; Ayatollahi, S.A.M. New cholinesterase-inhibiting triterpenoid alkaloids from Buxus hyrcana. Chem. Biodivers. 2006, 3, 1039–1052. [Google Scholar] [CrossRef] [PubMed]
Döpke, W.; Müller, B.; Und Jeffs, P.W. Buxarin und Buxenon, zwei neue Alkaloide aus Buxus sempervirens L. Die Pharm. Jahrg. 1966, 21, 643. [Google Scholar]
Ahmed, D.; Choudhary, M.I.; Turkoz, S.; Sener, B. Chemical Constituents of Buxus sempervirens. Planta Med. 1988, 54, 173–174. [Google Scholar] [PubMed]
Nakano, T.; Terao, S.; Saeki, Y. Buxus alkaloids. Part VII. The isolation and the constitutions of ten new alkaloids from the weak-base fractions of two species, B. microphylla Sieb. et Zucc. var. suffruticosa Makino and B. microphylla Sieb. et Zucc. var. suffruticosa Makino forma major Makino. J. Chem. Soc. C 1966, 1412. [Google Scholar]
Atta-ur-Rahman; Ahmed, D.; Choudhary, M.I.; Sener, B.; Turkoz, S. Alkaloids from the Leaves of Buxus sempervirens. J. Nat. Prod. 1988, 51, 783–786. [Google Scholar] [CrossRef]
Atta-ur-Rahman; Noor-e-ain, F.; Choudhary, M.I.; Parveen, Z.; Türköz, S.; Sener, B. New steroidal alkaloids from Buxus longifolia. J. Nat. Prod. 1997, 60, 976–981. [Google Scholar] [CrossRef]
Votický, Z.; Tomko, J. Alkaloids from Buxus sempervirens L. V. Configuration of buxtauine and buxpiine. Tetrahedron Lett. 1965, 6, 3579–3584. [Google Scholar] [CrossRef]
Kuchkova, K.I.; Voticky, Z.; Paulik, V. Buxus alkaloids. XIII. Alkaloids from Buxus sempervirens var. argentea Hort. ex. Steud. Chem. Zvesti 1976, 30, 174–178. [Google Scholar]
Atta-ur-Rahman; Naz, S.; Noor-e-ain, F.; Ali, R.A.; Choudhary, M.I.; Sener, B.; Turkoz, S. Alkaloids from Buxus species. Phytochemistry 1992, 31, 2933–2935. [Google Scholar] [CrossRef]
Loru, F.; Duval, D.; Aumelas, A.; Akeb, F.; Guédon, D.; Guedj, R. Four steroidal alkaloids from the leaves of Buxus sempervirens. Phytochemistry 2000, 54, 951–957. [Google Scholar] [CrossRef]
Döpke, W.; Härtel, R. N-Benzoylbuxodienin-E und N-Benzoyl-O-acetylbuxodienin-E—Zwei neue Alkaloide aus Buxus sempervirens L. Z. Chem. 1973, 13, 135–136. [Google Scholar] [CrossRef]
Devkota, K.P.; Lenta, B.N.; Fokou, P.A.; Sewald, N. Terpenoid alkaloids of the Buxaceae family with potential biological importance. Nat. Prod. Rep. 2008, 25, 612–630. [Google Scholar] [CrossRef] [PubMed]
Bienz, S.; Bigler, L.; Fox, T.; Meier, H. Spektroskopische Methoden in der Organischen Chemie; Georg Thieme Verlag: Stuttgart, Germany, 2016. [Google Scholar]
Meshkatalsadat, M.H.; Mollataghi, A.; Ata, A. New Triterpenoidal Alkaloids from Buxus hyrcana. Z. Naturforsch. B 2006, 61, 201–206. [Google Scholar] [CrossRef]
Černý, V.; Šorm, F. Chapter 8 Steroid Alkaloids: Alkaloids of Apocynaceae and Buxaceae; The Alkaloids: Chemistry and Physiology; Elsevier: Amsterdam, The Netherlands, 1967; pp. 305–426. [Google Scholar]
Blaschek, W.; Hager, H. (Eds.) Hagers Enzyklopädie der Arzneistoffe und Drogen. Mit 600 Tabellen; 6., neu bearb. und erg. Aufl.; Wiss. Verl.-Ges: Stuttgart, Germany, 2007. [Google Scholar]
Xiang, Z.-N.; Su, J.-C.; Liu, Y.-H.; Deng, B.; Zhao, N.; Pan, J.; Hu, Z.-F.; Chen, F.-H.; Cheng, B.-Y.; Chen, J.-C.; et al. Structurally diverse alkaloids from Buxus sempervirens with cardioprotective activity. Bioorg. Chem. 2021, 109, 104753. [Google Scholar] [CrossRef]
Theodorou, V.; Skobridis, K.; Tzakos, A.G.; Ragoussis, V. A simple method for the alkaline hydrolysis of esters. Tetrahedron Lett. 2007, 48, 8230–8233. [Google Scholar] [CrossRef]
Nnadi, C.O.; Nwodo, N.J.; Kaiser, M.; Brun, R.; Schmidt, T.J. Steroid Alkaloids from Holarrhena africana with Strong Activity against Trypanosoma brucei rhodesiense. Molecules 2017, 22, 1129. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Bernal, F.A.; Kaiser, M.; Wünsch, B.; Schmidt, T.J. Structure-Activity Relationships of Cinnamate Ester Analogues as Potent Antiprotozoal Agents. Chem. Med. Chem. 2020, 15, 68–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Mahmoud, A.B.; Mäser, P.; Kaiser, M.; Hamburger, M.; Khalid, S. Mining Sudanese Medicinal Plants for Antiprotozoal Agents. Front. Pharmacol. 2020, 11, 865. [Google Scholar] [CrossRef] [PubMed]

Figure 1. Core skeletons of isolated Buxus-alkaloids 1–25. For complete structures, see Table 1.

Scheme 1. From the leaves of B. sempervirens L. Abbreviations: lipophilic and neutral fraction (LNB); alkaloid fraction (ALOF); centrifugal partition chromatography (CPC); fraction (F); and test tube (TT).

Figure 2. Chemical structure of the new natural products 3, 4, 7, 8, 11 and 23–25.

Table 1. Chemical structures of isolated Buxus-alkaloids 1–25. For core skeletal structures see Figure 1.

Cpd	Structure
	Core skeleton A:
1	R₁₊₄: H, R₂: N(CH₃)₂, R₃: (CH₃)₂, Δ⁶, R₅: O-tiglate, R₆: NHCH₃
2	R₁₊₄: H, R₂: N(CH₃)₂, R₃: (CH₃)₂, Δ⁶, R₅: OH, R₆: NHCH₃
3	R₁₊₄: H, R₂: N(CH₃)₂, R₃: CH₃+CH₂OH, Δ⁶, R₅: O-tiglate, R₆: NHCH₃
4	R₁₊₄: H, R₂: N(CH₃)₂, R₃: CH₃+CH₂OH, Δ⁶, R₅: O-tiglate, R₆: N(CH₃)₂
5	R₁₊₄: H, R₂: N(CH₃)₂, R₃: CH₃+CH₂OH, Δ⁶, R₅: OH, R₆: N(CH₃)₂
6	R₁₊₄: H, R₂: N(CH₃)₂, R₃: CH₃+CH₂OH, Δ⁶, R₅: O-benzoate, R₆: N(CH₃)₂
7	R₁₊₄: H, R₂: N(CH₃)₂, R₃: CH₃+CH₂OH, Δ⁶, R₅: O-benzoate, R₆: NHCH₃
8	R₁: O-benzoate, R₂: NHCH₃, R₃: (CH₃)₂, R₄₊₅: H, R₆: NHCH₃
9	R₁₊₅: H, R₂: benzamide, R₃: CH₃+CH₂OAc, R₄: =O, R₆: N(CH₃)₂
10	R₁₊₅: H, R₂: benzamide, R₃: CH₃+CH₂OH, R₄: =O, R₆: N(CH₃)₂
11	R₁₊₄: H, R₂: =O, R₃: CH₃+CH₂OH, R₅: OH, R₆: N(CH₃)₂
12	R₁₊₄: H, Δ^1,2, R₂: =O, R₃: (CH₃)₂, R₅: OH, R₆: N(CH₃)₂
13	R₁₊₄₊₆: H, R₂: NHCH₃, R₃: (CH₃)₂, R₅: =O, Δ¹⁷⁽²⁰⁾ (E)
14	R₁₊₄₊₆: H, R₂: NHCH₃, R₃: (CH₃)₂, R₅: =O, Δ¹⁷⁽²⁰⁾ (Z)
15	R₁₊₄₊₆: H, R₂: NHCH₃, R₃: =CH₂, R₅: =O, Δ¹⁷⁽²⁰⁾ (E)
16	R₁₊₄₊₆: H, R₂: NHCH₃, R₃: =CH₂, R₅: =O, Δ¹⁷⁽²⁰⁾ (Z)
17	R₁₊₄: H, R₂: NHCH₃, R₃: =CH₂, R₅: OH, R₆: =O
18	R₁₊₄: H, R₂: N(CH₃)₂, R₃: =CH₂, R₅: OH, R₆: =O
	Core skeleton B:
19	R₁: OH, R₂: N(CH₃)₂
	Core skeleton C:
20	R₁: N(CH₃)₂, R₂: OH, R₃: H_, R₄: =O
21	R₁: N(CH₃)₂, R₂₊₃: H, R₄: NHAc
22	R₁: N(CH₃)₂, R₂: OAc, R₃: H_, R₄: benzamide
23	R₁: N(CH₃)₂, R₂: OAc, R₃: H_, R₄: benzamide
24	R₁: NHCH₃, R₂₊₃: H, R₄: NHAc
25	R₁: NHCH₃, R₂: H, R₃₊₄: OH

Table 2. ¹H- and ¹³C-NMR data of compounds 3 (600/150 MHz, CDCl₃), 4, 7 and 8 (600/150 MHz, CD₃OD).

	3		4		7		8
Pos.	δ_C [ppm]	δ_H [ppm], mult., J [Hz]	δ_C [ppm]	δ_H [ppm], mult., J [Hz]	δ_C [ppm]	δ_H [ppm], mult., J [Hz]	δ_C [ppm]	δ_H [ppm], mult., J [Hz]
1	29.82, CH₂	1.74, d, 12.4 1.69, m	31.72, CH₂	1.63, m (2H)	30.44, CH₂	1.75, m (2H)	38.75, CH₂	1.98, dd, 12.5, 4.9 1.79, m
2	20.01, CH₂	1.96, m 1.87, m	19.62, CH₂	1.82, m 1.68, m	20.94, CH₂	2.07, dd, 12.5, 3.5 1.92, m	74.49, CH	5.30, td, 10.9, 4.8
3	72.94, CH	3.46, dd, 12.8, 3.5	73.29, CH	2.71, dd, 12.3, 3.4	75.62, CH	3.49, m	73.20, CH	3.35, d, 11.0
4	42.69, qC	-	43.36, qC	-	43.21, qC	-	41.53, qC	-
5	43.78, CH	2.19, m	45.82, CH	1.95, s	45.18, CH	2.11, br s	48.78, CH	1.73, m
6	125.03, CH	5.54, d, 10.8	126.72, CH	5.49, m	126.06, CH	5.52, m	21.93, CH₂	1.77, m 0.94, m
7	129.83, CH	5.50, ddd, 10.8, 5.8, 2.8	130.42, CH	5.45, ddd, 10.6, 5.8, 2.9	130.96, CH	5.56, m	26.75, CH₂	1.47, m 1.23, m
8	42.71, CH	2.65, m	44.49, CH	2.63, m	44.05, CH	2.74, m	48.95, CH	1.66, dd, 12.5, 4.8
9	20.74, qC	-	21.72, qC	-	21.80, qC	-	20.91, qC	-
10	27.32, qC	-	29.07, qC	-	28.55, qC	-	25.47, qC	-
11	24.83, CH₂	1.90, dd, 14.6, 4.7 1.46, m	26.07, CH₂	1.90, m 1.51, m	25.74, CH₂	1.99, m 1.58, m	27.10, CH₂	2.11, m 1.22, m
12	31.87, CH₂	1.84, dd, 13.1, 4.3 1.48, m	33.43, CH₂	1.76, dd, 13.5, 5.1 1.46, m	33.13, CH₂	1.92, m 1.62, dd, 13.5, 5.0	33.11, CH₂	1.75, m 1.73, m
13	47.53, qC	-	46.27, qC	-	47.88, qC	-	46.89, qC	-
14	49.48, qC	-	50.79, qC	-	50.35, qC	-	50.04, qC	-
15	42.33, CH₂	2.16, m 1.44, m	43.28, CH₂	2.08, m 1.11, d, 13.9	43.59, CH₂	2.39, dd, 14.7, 8.7 1.46, dd, 14.6, 1.2	36.46, CH₂	1.56, m 1.52, m
16	78.68, CH	5.26, dd, 8.3, 5.5	81.26, CH	5.12, ddd, 8.5, 5.9, 1.0	80.89, CH	5.28, ddd, 8.3, 6.4, 1.3	27.01, CH₂	2.02, m 1.58, m
17	55.41, CH	2.46, dd, 10.8, 5.5	56.84, CH	2.21, m	55.65, CH	2.58, dd, 10.8, 6.3	51.04, CH	2.06, m
18	15.77, CH₃	1.04, s	16.28, CH₃	1.00, s	15.91, CH₃	1.13, s	18.68, CH₃	1.08, s
19	17.94, CH₂	0.83, d, 4.4 −0.03, d, 4.4	19.09, CH₂	0.79, d, 4.1 −0.07, d, 4.2	18.61, CH₂	0.85, d, 4.3 0.08, d, 4.5	30.11, CH₂	0.80, d, 4.6 0.71, d, 4.6
20	57.14, CH	3.41, m	61.37, CH	2.63, m	58.42, CH	3.58, m	60.44, CH	3.24, m
21	15.45, CH₃	1.41, d, 6.5	10.53, CH₃	0.89, d, 6.4	15.54, CH₃	1.41, d, 6.5	15.45, CH₃	1.31, d, 6.4
28	17.45, CH₃	0.98, s	18.16, CH₃	0.98, s	18.46, CH₃	1.04, s	19.71, CH₃	1.01, s
29	67.80, CH₂	4.05, d, 11.6 3.79, d, 11.5	72.91, CH₂	3.81, d, 10.4 3.52, d, 10.3	70.91, CH₂	3.92, m 3.65, m	25.16, CH₃	1.20, s
30	12.89, CH₃	1.10, s	12.78, CH₃	1.05, s	12.31, CH₃	1.14, s	15.76, CH₃	1.06, s
31/32	45.64, CH₃	2.96, s (3H)	42.94, CH₃	2.37, s (6H)	45.40, CH₃	2.94, s (3H)	37.69, CH₃	2.96, s (3H)
	39.09, CH₃	2.77, s (3H)			39.31, CH₃	2.78, s (3H)
33/34	29.06, CH₃	2.66, s (3H)	40.71, CH₃	2.14, s (6H)	30.01, CH₃	2.69, s (3H)	29.88, CH₃	2.67, s (3H)
OCO					167.54, qC	-	166.74, qC	-
1′	169.61, qC	-	169.27, qC	-	131.45, qC	-	130.97, qC	-
2′	127.74, qC	-	130.20, qC	-	130.48, CH	8.03, m	130.53, CH	8.06, m
3′	141.17, CH	6.91, qq, 7.0, 1.4	137.75, CH	6.80, qq, 7.0, 1.3	129.76, CH	7.50, m	129.95, CH	7.53, m
4′	14.81, CH₃	1.81, m	14.31, CH₃	1.79, m	134.55, CH	7.63, m	134.86, CH	7.66, m
5′	11.90, CH₃	1.80, m	12.16, CH₃	1.81, m	129.76, CH	7.50, m	129.95, CH	7.53, m
6′					130.48, CH	8.03, m	130.53, CH	8.06, m

Table 3. ¹H- and ¹³C-NMR data of compounds 11, 23 (600/150 MHz, CD₃OD), 24 and 25 (600/150 MHz, CDCl₃).

	11		23		24		25
Pos.	δ_C [ppm]	δ_H [ppm], mult., J [Hz]	δ_C [ppm]	δ_H [ppm], mult., J [Hz]	δ_C [ppm]	δ_H [ppm], mult., J [Hz]	δ_C [ppm]	δ_H [ppm], mult., J [Hz]
1	33.21, CH₂	1.91, m 1.57, m	121.95, CH	5.42, br s	117.16, CH	5.39, s	116.85, CH	5.39, br s
2	38.83, CH₂	2.68, m 2.29, m	22.98, CH₂	2.19, m (2H)	24.92, CH₂	2.43, m 2.28, m	24.91, CH₂	2.46, m 2.33, m
3	217.33, qC	-	68.30, CH	2.19, m	65.73, CH	2.80, m	65.87, CH	2.78, m
4	56.13, qC	-	39.17, qC	-	36.60, qC	-	36.46, qC	-
5	42.14, CH	2.33, m	52.91, CH	1.73, m	50.90, CH	1.87, m	50.51, CH	1.87, m
6	22.08, CH₂	1.62, m 1.01, dd, 12.6, 2.4	31.54, CH₂	1.97, m 1.73, m	29.98, CH₂	2.04, m 1.30, m	31.38, CH₂	2.10, m 1.26, m
7	26.98, CH₂	1.38, m (2H)	28.41, CH₂	1.54, dd, 14.0, 5.7 1.44, m	27.79, CH₂	1.69, m 1.44, m	27.47, CH₂	1.64, m 1.48, m
8	49.18, CH	1.61, m	48.47, CH	2.03, m	47.44, CH	2.03, m	48.46, CH	2.04, d, 10.2
9	21.31, qC	-	141.29, qC	-	138.47, qC	-	138.16, qC	-
10	26.69, qC	-	141.10, qC	-	140.39, qC	-	140.55, qC	-
11	27.24, CH₂	2.21, m 1.26, m	119.37, CH	5.31, br m	120.81, CH	5.29, s	120.60, CH	5.35, br s
12	32.60, CH₂	1.86, m 1.66, m	37.85, CH₂	2.19, m 1.99, m	36.97, CH₂	1.97, m 1.90, m	30.87, CH₂	2.40, m 1.64, m
13	47.36, qC	-	45.34, qC	-	44.02, qC	-	48.06, qC	-
14	48.90, qC	-	48.45, qC	-	48.81, qC	-	48.53, qC	-
15	48.01, CH₂	2.06, m 1.48, dd, 13.9, 2.3	43.83, CH₂	2.01, m 1.32, dd, 14.3, 1.4	32.93, CH₂	1.43, m 1.34, m	33.30, CH₂	1.55, m 1.48, m
16	77.20, CH	4.31, m	80.73, CH	5.02, ddd, 8.9, 6.6, 1.4	26.47, CH₂	1.83, m 1.46, m	38.63, CH₂	2.14, m 1.90, m
17	56.12, CH	2.23, m	58.04, CH	2.34, dd, 10.8, 6.6	51.73, CH	1.76, m	85.50, qC	-
18	19.65, CH₃	1.13, s	16.62, CH₃	0.84, s	15.57, CH₃	0.73, s	17.64, CH₃	0.73, s
19	30.56, CH₂	0.83, d, 4.1 0.68, d, 4.4	47.16, CH₂	2.93, d, 14.2 2.78, d, 14.3	45.87, CH₂	2.93, m 2.82, m	46.11, CH₂	2.96, d, 14.6 2.82, m
20	68.22, CH	3.59, m	48.17, CH	4.40, dq, 13.2, 6.5	49.31, CH	3.99, m	73.74, CH	3.84, q, 6.1
21	11.36, CH₃	1.32, d, 6.6	20.74, CH₃	1.27, d, 6.6	21.30, CH₃	1.14, d, 6.3	18.21, CH₃	1.18, d, 6.1
28	21.28, CH₃	1.23, s	17.89, CH₃	0.92, s	17.49, CH₃	0.72, s	18.56, CH₃	1.03, s
29	64.35, CH₂	3.86, d, 11.2 3.32, m	29.41, CH₃	0.93, s	26.31, CH₃	1.15, s	27.32, CH₃	1.14, s
30	16.98, CH₃	0.97, s	22.83, CH₃	1.00, s	18.22, CH₃	1.01, s	19.97, CH₃	1.09, s
31/32			45.32, CH₃	2.30, s (6H)	33.38, CH₃	2.72, s (3H)	34.09, CH₃	2.75, s (3H)
33/34	43.67, CH₃	2.96, s (3H)
	36.65, CH₃	2.81, s (3H)
Ac-CH₃			20.97, CH₃	1.62, s	23.35, CH₃	1.99, s
Ac-CO			172.40, qC	-	170.18, qC	-
OCNH			168.61, qC	-	-	5.46, d (1H), 9.0
1′			135.84, qC	-
2′			128.28, CH	7.78, m
3′			129.45, CH	7.44, m
4′			132.54, CH	7.51, m
5′			129.45, CH	7.44, m
6′			128.28, CH	7.78, m

Table 4. In vitro antiprotozoal and cytotoxic activity of isolated Buxus-alkaloids.

Cpd	Pf	Tbr	Cytotox.	SI Pf	SI Tbr
1	0.52 ± 0.14 (1.05 µM)	1.6 ± 0.55 * (3.2 µM)	9.4 ± 3.8 (19 µM)	18	6
2	1.07 ± 0.11 (2.6 µM)	0.6 ± 0.03 (1.5 µM)	14.7 ± 3.1 (35.5 µM)	14	25
3	0.5 ± 0.06 (0.98 µM)	4.6 ± 0.005 (9 µM)	35.8 ± 13.6 (69.9 µM)	72	8
4	0.35 ± 0.08 (0.7 µM)	1.5 ± 0.76 * (2.9 µM)	12 ± 1.4 (22.8 µM)	34	8
5	0.78 ± 0.08 (1.76 µM)	1.04 ± 0.27 * (2.34 µM)	44 ± 2.3 (99 µM)	56	42
6	0.4 ± 0.02 (0.7 µM)	0.69 ± 0.06 (1.3 µM)	9.3 ± 3 (17 µM)	23	14
7	0.11 ± 0.01 (0.2 µM)	1.9 ± 0.3 (3.6 µM)	16 ± 0.2 (29.9 µM)	145	8
8	0.09 ± 0.03 * (0.18 µM)	0.55 ± 0.18 (1.1 µM)	6.65 ± 0.38 (13.1 µM)	74	12
9	2.15 ± 0.29 (3.8 µM)	1.35 ± 0.45 * (2.4 µM)	41 ± 0.7 (73 µM)	19	30
11	0.9 ± 0.13 (2.2 µM)	2.9 ± 1 (7 µM)	44 ± 1.3 (105.4 µM)	49	15
12	1.4 ± 0.44 * (3.5 µM)	2.5 ± 0.1 (6.3 µM)	19 ± 1.2 (47.6 µM)	14	8
13 + 14	1.6 ± 0.18 * (4.3 µM)	0.8 ± 0.06 (2.2 µM)	5.3 ± 0.05 (14.4 µM)	3	7
15 + 16	1.1 ± 0.01 (3.1 µM)	0.75 ± 0.001 (2.1 µM)	10.4 ± 4.17 (29.4 µM)	9	14
17	4.1 ± 0.8 (10.9 µM)	48 ± 0.2 (129.3 µM)	30.5 ± 9.6 (82 µM)	7	0.6
18	2.6 ± 0.005 (6.8 µM)	16.9 ± 2.3 (44 µM)	26.8 ± 8.8 (69.6 µM)	10	2
19	1.3 ± 0.35 * (3.8 µM)	2.2 ± 0.07 (6.4 µM)	13.4 ± 0.5 (38.8 µM)	10	6
20	1.6 ± 0.57 * (4 µM)	5.26 ± 0.3 (13.2 µM)	45 ± 1 (112.7 µM)	28	9
21	3.1 ± 0.24 * (7.3 µM)	53 ± 1 (124 µM)	54.8 ± 1.1 (129 µM)	18	1
22	3 ± 0.3 (6.2 µM)	3.4 ± 1 (6.2 µM)	8.5 ± 0.1 (15.6 µM)	3	3
23	4.2 ± 0.4 (7.7 µM)	3.1 ± 0.6 (5.7 µM)	27.5 ± 16 (50.4 µM)	7	9
24	2.3 ± 0.27 (5.6 µM)	0.52 ± 0.27 * (1.3 µM)	16.9 ± 1.1 (41 µM)	7	33
25	3.6 ± 0.05 (9.3 µM)	6.7 ± 0.49 (17.3 µM)	44.5 ± 5.5 (114.9 µM)	12	7
Chloroquine	0.006 ± 0.001 (0.019 µM)
Melarsoprol		0.005 ± 0.001 (0.013 µM)
Podophyllotoxin			0.006 ± 0.001 (0.014 µM)

All IC₅₀ values are expressed in µg/mL and values in µM are given in parentheses. While * n = 3 was reported as the mean value from three independent measurements with the standard deviation, all other values were determined with n = 2 as the mean value from two independent measurements with the fluctuation range. Note that the purity of compound 10 was <90%, so that activity was not determined.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Share and Cite

MDPI and ACS Style

Szabó, L.U.; Kaiser, M.; Mäser, P.; Schmidt, T.J. Antiprotozoal Nor-Triterpene Alkaloids from Buxus sempervirens L. Antibiotics 2021, 10, 696. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10060696

AMA Style

Szabó LU, Kaiser M, Mäser P, Schmidt TJ. Antiprotozoal Nor-Triterpene Alkaloids from Buxus sempervirens L. Antibiotics. 2021; 10(6):696. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10060696

Chicago/Turabian Style

Szabó, Lara U., Marcel Kaiser, Pascal Mäser, and Thomas J. Schmidt. 2021. "Antiprotozoal Nor-Triterpene Alkaloids from Buxus sempervirens L." Antibiotics 10, no. 6: 696. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10060696

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Antiprotozoal Nor-Triterpene Alkaloids from Buxus sempervirens L.

Abstract

1. Introduction

2. Results and Discussion

2.1. Identification of Isolated Buxus-Alkaloids

2.2. In Vitro Antiprotozoal Activity of Isolated Compounds

3. Materials and Methods

3.1. Plant Material

3.2. Extraction and Isolation of Alkaloids from the B. sempervirens Leaf Extract

3.3. Alkaline Hydrolysis of the Esters 1 and 6

3.4. Spectroscopic Analysis of Isolated Compounds

3.5. Spectral Data of Isolated Buxus-Alkaloids

3.6. In Vitro Bioassays

4. Conclusions

Supplementary Materials

Author Contributions

Funding

Institutional Review Board Statement

Informed Consent Statement

Data Availability Statement

Acknowledgments

Conflicts of Interest

References

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI